Clinical trial register · European Union · CTIS

EU Clinical Trials Tracker

Name: EU clinical trials authorised under CTIS
Creator: Priya Life Science
License: https://www.ema.europa.eu/en/about-us/legal-notice

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.

Download CSV

Source: EMA Clinical Trials Information System (CTIS). Showing the 2557 most recently authorised of 12788 total CTIS records — a stated recency window, not the full historical archive. Synced 07 Nov 2026, 03:17 UTC

2557

Shown in this register

most recently authorised

12,788

Total on CTIS

full historical archive

789

Phase III

within the shown window

Top member states

Spain 1074 France 933 Germany 893 Italy 777 Poland 614 Netherlands 544

Narrow the registerReset

Search within results

Phase

Lead sponsor

Member state

All 28 states

Trials in this register

Phase

Study

Lead sponsor

Area

Member states

Decision

Phase II

Metformin Effect in Optical Coherence Tomography Prognosis Biomarkers and Disease Progression in Intermediate Age-related Macular Degeneration

2025-522990-12-00Intermediate Age-related Macular Degeneration (iAMD)

Unidade Local De Saude De Sao Jose E.P.E.

Eye Diseases

Portugal

06/11/2026

Phase II

"EURbG2": A European prospective study of patients with unilateral retinoblastoma requiring enucleation, either first-line or after neoadjuvant chemotherapy, with analysis of histological risk factors and biomarkers at baseline and during follow-up

2024-515962-15-00Retinoblastoma

DrugsThiotepa·Vincristine·Etoposide·Cyclophosphamide

Institut Curie

Eye Diseases

France

06/11/2026

Phase II

EPIC-BURN: Intraindividual, blinded, Phase 2aRCT Comparing Autologous Epidermal Cell Suspension (Epi-001) vs. Standard of care (meshed Meek micrograft) for treatment of Deep Dermal and Full-Thickness Burn Wounds

2026-527004-25-00Deep dermal and full-thickness burn wounds

Region Oestergoetland

Skin and Connective Tissue Diseases

Sweden

06/11/2026

Phase II

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, 52-Week Study Evaluating the Efficacy and Safety of Apitegromab in Participants With Facioscapulohumeral Muscular Dystrophy (FORGE)

2026-525204-10-00Facioscapulohumeral Muscular Dystrophy

DrugApitegromab

Scholar Rock Inc.

Musculoskeletal Diseases

Italy, Spain

05/11/2026

Phase II

A Phase 2, Multicenter, Randomized, Parallel Treatment Arms, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of CP-012B in Participants with Parkinson’s Disease with Early Morning OFF Episodes

2026-526634-46-00Parkinson’s Disease With Early Morning OFF Episodes

Contera Pharma A/S

Nervous System Diseases

Italy, Spain

05/11/2026

Phase II

METIMMOX-3: Using Tumor Mutational Status as Selection Biomarker for First-Line Therapy with Short-Course Oxaliplatin-Based Chemotherapy and Bevacizumab Alternating with Tislelizumab in Metastatic MSS/pMMR Colorectal Cancer

2026-526317-29-00Metastatic colorectal cancer

DrugsFluorouracil·Tislelizumab·Oxaliplatin·Bevacizumab

Akershus University Hospital

Digestive System Diseases

Norway

05/11/2026

Phase II

A Randomized, Double-Blind, Placebo-Controlled, Multi-centre Study to Evaluate the Pharmacodynamic Effects of Teverelix DP, a GnRH Antagonist, on Prostate Volume and Urinary Function in Men following a First Episode of Acute Urinary Retention (AUR)

2026-525963-41-00Acute Urinary Retention

Antev Limited

Male Urogenital Diseases

Bulgaria, Lithuania, Czechia

03/11/2026

Phase II

A Phase IIb multicenter, randomized, double-blind, placebo-controlled, dose-range study to assess the efficacy and safety of GIA632 in participants with moderate to severe cutaneous lichen planus, followed by an extension period

2025-522300-25-00Cutaneous lichen planus

DrugGIA632

Novartis Pharma AG

Immune System Diseases

Italy, Germany, Spain, France

02/11/2026

Phase II

PHASE II RANDOMISED CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PAPAVERINE IN PREVENTING ARTERIAL VASOSPASM AND REDUCING POSTOPERATIVE HYPOPARATHYROIDISM IN ADULT PATIENTS UNDERGOING TOTAL THYROIDECTOMY – PPPTH trial

2026-527270-37-00Patients affected by benign or malignant thyroid disease

DrugPapaverine

Azienda Provinciale Per I Servizi Sanitari

Hormonal diseases

Italy

02/11/2026

Phase II

Diagnostic Performance of [⁶⁸Ga]Ga-HKG301 (FAP-2286) PET/CT in Biologic Borderline Resectable Pancreatic and Invasive Lobular Breast Cancers – FAPTRACE Trial

2026-526498-40-00Pancreatic adenocarcinoma, Invasive lobular breast cancer

DrugAAA514

Gemeinnuetzige Salzburger Landeskliniken Betriebsgesellschaft mbH

Neoplasms

Austria

01/11/2026

Phase II

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study of ALN-CIDEB in Adults with Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)

2026-525916-33-00Metabolic Dysfunction-Associated Steatohepatitis (MASH)

DrugAln-Cideb

Regeneron Pharmaceuticals Inc.

Nutritional and Metabolic Diseases

Spain, Italy

30/10/2026

Phase II

Multicenter, open-label, randomized Phase 2 study evaluating continuous weekly dosing of ficerafusp alfa (BCA101) in combination with pembrolizumab versus an alternative dosing regimen for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma

2026-526741-10-00Recurrent or Metastatic Head and Neck Squamous Cell Carcino…

DrugsFicerafusp alfa·Pembrolizumab

Bicara Therapeutics Inc.

Neoplasms

Netherlands, Spain, France, Italy, Belgium, Poland, Germany

30/10/2026

Phase II

SAKK 18/25: Overcoming Resistance to Immunotherapy combining Gemcitabine with Ivonescimab in advanced NSCLC progressing on immune checkpoint inhibitors: A multicenter, single-arm, open-label phase II trial (ORIGIN2)

2026-526043-36-00advanced NSCLC

DrugsIvonescimab·Gemcitabine

Swiss Cancer Institute, Cancer Trials Ireland

Neoplasms

Ireland

30/10/2026

Phase II

A pilot TriAl of psilocybiN-Assisted psychotherapy for the treatment Of Sex addiction

2026-527083-32-00Sex addiction

DrugPsilocybine

Centre Hospitalier Universitaire De Nantes

Behavior and Behavior Mechanisms

France

30/10/2026

Phase II

(VVD-133214-02 / 23236) A Phase 2, Randomized, Open-label Study of VVD-133214 in Combination with Pembrolizumab compared to Pembrolizumab Monotherapy in Participants with Advanced Colorectal Adenocarcinoma (CRC) Harboring Microsatellite Instability (MSI) and/or Deficient Mismatch Repair (DMMR)

2026-525507-26-00Advanced colorectal adenocarcinoma

DrugsVVD-133214·Pembrolizumab

Vividion Therapeutics Inc.

Neoplasms

Greece, Portugal, Italy, France, Belgium, Germany, Spain

30/10/2026

Phase II

Use of Dapagliflozin in Primary Prevention of Cardiotoxicity of Anthracycline Chemotherapy in Breast Cancer Patients (Alpaca)

2026-525705-13-00Breast cancer, patients treated with anthracycline chemothe…

DrugDapagliflozin

Institute Of Oncology Ljubljana, University Medical Center Ljubljana

Cardiovascular Diseases

Slovenia

29/10/2026

Phase II

Immunotherapy with a JAK1/JAK2 inhibitor (baricitinib) and an mTORC1 inhibitor (sirolimus), alone and in combination, for the control of HIV-1 replication after antiretroviral treatment interruption: a phase II multicenter, multi-arm, multi-stage, randomized, double-blind, placebo-controlled, adaptative trial

2025-523118-97-00HIV-1 Infection

DrugsBaricitinib·Sirolimus

ANRS Maladies Infectieuses Emergentes

Virus Diseases

France

27/10/2026

Phase II

A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with Previously Treated, Advanced KRAS G12D-Mutated Non-Small Cell Lung Cancer (TARGET-D 202)

2026-526472-23-00Non-Small Cell Lung Cancer

Verastem Inc.

Neoplasms

France, Spain, Germany, Italy, Belgium

27/10/2026

Phase II

A Phase 2, Double-blind, Randomized, Placebo-controlled, Multicenter Trial to Assess the Efficacy, Safety, and Tolerability of AGMB-447 in Participants with Idiopathic Pulmonary Fibrosis

2026-526404-71-00Idiopathic Pulmonary Fibrosis

DrugSalbutamol

Agomab Spain S.L.U.

Respiratory Tract Diseases

Poland, France, Belgium, Italy, Spain, Portugal, Netherlands, Germany

27/10/2026

Phase II

In vivo biological standardization of Cynodon Dactylon allergen extracts. EBEA-C STUDY

2025-522597-37-00Allergies

Asac Pharmaceutical Inmunology S.A.

Diagnosis

Spain

27/10/2026

Phase II

A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF RO7568282 IN PARTICIPANTS WITH EARLY SYMPTOMATIC ALZHEIMER’S DISEASE

2026-526158-14-00Early Symptomatic Alzheimer’s Disease (AD)

DrugRO7568282

F. Hoffmann-La Roche AG

Nervous System Diseases

Spain, Belgium, Denmark, France, Poland, Italy, Germany, Ireland

27/10/2026

Phase II

New diagnostic pathway in primary diagnosis of clinically significant prostate cancer adding PSMA-PET to mpMRI

2026-527906-19-00Clinically significant prostate cancer

Klinikum der Technischen Universitaet Muenchen (TUM Klinikum)

Male Urogenital Diseases

Germany

27/10/2026

Phase II

A Phase 2 open-label trial to investigate the long term safety of VO659 administered intrathecally in participants with Huntington’s disease and spinocerebellar ataxia type 1 and 3

2026-526408-60-00Spinocerebellar ataxia types 1, 3 and Huntington's disease

Vico Therapeutics B.V.

Nervous System Diseases

Denmark, France, Netherlands, Germany

26/10/2026

Phase II

Reducing Oxidative Stress after Cardiac arrest (ROSC): A Phase II Randomized Controlled Trial

2025-525094-37-00Out of Hospital Cardiac Arrest (OHCA)

DrugAcetylcysteine

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Cardiovascular Diseases

Netherlands

22/10/2026

Phase II

Effects of Anti-IL33 (Tozorakimab) Upon Airway Inflammation, Remodelling and Response to Exacerbation Triggers in COPD (The MAB Trial)

2025-522359-24-00COPD

DrugTozorakimab

University Of Leicester

Respiratory Tract Diseases

Spain, Netherlands, Italy, Denmark

22/10/2026

Phase II

Aspire-202: A Phase 2 Multi-center, Randomized, Open-label Study to Assess the Efficacy and Safety of AHB-137 in Nucleos(t)ide Analogue-treated Participants with Chronic Hepatitis B in the North America and Europe Regions

2025-524159-30-00Chronic Hepatitis B

DrugAHB-137

Ausperbio Therapeutics Inc.

Virus Diseases

France, Italy, Spain

22/10/2026

Phase II

"PREVENTAMI-FX — PREvention of VENtricular Thrombosis in Acute Myocardial Infarction with FondaparinuX"

2025-524664-38-00Acute anterior myocardial infarction with systolic dysfunct…

DrugsPrasugrel·Acetylsalicylic acid·Ticagrelor·Clopidogrel

Azienda Unita' Sanitaria Locale Toscana Sud Est

Cardiovascular Diseases

Italy

21/10/2026

Phase II

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of RO7568282 in Participants with Early-Stage Parkinson’s Disease

2025-524064-37-00Parkinson’s Disease (PD)

DrugRO7568282

F. Hoffmann-La Roche AG

Nervous System Diseases

Germany, Italy, Netherlands, Poland, France, Ireland, Spain, Austria

21/10/2026

Phase II

A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, With and Without an Anti-EGFR Antibody, and With an Anti-EGFR Antibody and Chemotherapy, in Patients With Metastatic KRAS G12D-Mutated Colorectal Adenocarcinoma (TARGET-D 203)

2026-526473-42-00Metastatic KRAS G12D-Mutated Colorectal Adenocarcinoma

DrugsPanitumumab·Erbitux·Fluorouracil·Oxaliplatin

Verastem Inc.

Neoplasms

Italy, Spain, France, Germany, Belgium

20/10/2026

Phase II

A Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Multiple Subcutaneous Doses of TRIV-573 in Participants with Moderate to Severe Atopic Dermatitis

2026-526485-25-00Atopic dermatitis

Triveni Bio Inc.

Skin and Connective Tissue Diseases

Czechia, Poland

20/10/2026

Phase II

RELIEVE (RandomizEd triaL of Intravesical xEomin for incontinence via the VibE system) - a randomized, prospective, multicenter, double blind, placebo and sham controlled study to assess the safety and efficacy of NT 201 intravesical administration using Vibe System in the treatment of female participants suffering from idiopathic overactive bladder

2026-526512-36-00Idiopathic Overactive Bladder (OAB)

Vensica Medical Ltd.

Female Urogenital Diseases and Pregnancy Complications

Portugal, Italy, Czechia, Poland

20/10/2026

Phase II

An Open-Label Extension, One-Year, Safety, and Efficacy Study of SPN-817 in Adults With Focal Onset Seizures

2026-526361-15-00Focal Onset Seizures

DrugHuperzine A

Supernus Pharmaceuticals Inc.

Nervous System Diseases

Poland, Bulgaria, Hungary

20/10/2026

Phase II

An open-label, phase 2 pilot study on the efficacy and safety of Piclidenoson in patients with Lowe syndrome

2026-525495-26-00Lowe Syndrome

Can-Fite Biopharma Ltd.

Nutritional and Metabolic Diseases

Italy

19/10/2026

Phase II

PET-Guided Navigation with Electromagnetic Tracking during PSMA-RadioGuided Surgery: Innovative Bimodal Detection of Nodal Metastases in Prostate Cancer Patients

2026-526915-12-00Prostate Cancer

Ospedale San Raffaele S.r.l.

Male Urogenital Diseases

Italy

19/10/2026

Phase II

EORTC-2456-LCG-BTG: A randomized phase II study evaluating upfront SRT to all brain metastases followed by ivonescimab plus chemotherapy versus upfront ivonescimab plus chemotherapy in patients with asymptomatic active brain metastases from NSCLC.

2025-522985-60-00Non-small cell lung cancer

DrugsIvonescimab·Paclitaxel·Carboplatin

European Organisation For Research And Treatment Of Cancer

Neoplasms

Slovenia, Spain, Germany, France, Austria, Netherlands, Italy, Greece

19/10/2026

Phase II

Anti-HER2 treatment Discontinuation Guided by ctDNA in Patients with HER2-Positive Metastatic Breast Cancer with Sustained Disease Control: PHENIX Trial

2026-526268-18-00Breast Cancer

DrugsPhesgo·Pertuzumab

Fundacion Para El Fomento De La Investigacion Sanitaria Y Biomedica De La Comunitat Valenciana

Neoplasms

Spain

19/10/2026

Phase II

A Double-Blind, Placebo-Controlled, Multicenter, Randomized, Phase 2 Trial to Evaluate the Safety and Efficacy of Mezagitamab (TAK-079) in Kidney Transplant Recipients With Late Antibody-Mediated Rejection (AMR)

2026-526239-20-00Late antibody mediated rejection (AMR)

DrugMezagitamab

Takeda Development Center Americas Inc.

Immune System Diseases

Germany, France

19/10/2026

Phase II

A Multinational Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety and Efficacy of Mirivadelgat, an Aldehyde Dehydrogenase 2 Activator, in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD); the WINDWARD study

2026-526703-30-00Pulmonary Hypertension associated with Interstitial Lung Di…

Foresee Pharmaceuticals USA Inc.

Respiratory Tract Diseases

Spain, Hungary, Czechia

19/10/2026

Phase II

A Pragmatic Phase II Study to Optimize Neoadjuvant Treatment and Surgical De-escalation in HR+/HER2− Early Breast Cancer Using Oncotype DX and Abemaciclib - VIOLET trial

2026-525457-37-00HER2-negative, stage II–IIIB, neoadjuvant chemotherapy, est…

DrugsAbemaciclib·Paclitaxel

Istituto Di Ricerche Farmacologiche Mario Negri

Neoplasms

Italy

16/10/2026

Phase II

A pilot multicentric open study assessing the efficacy and safety of NEMOlizumab in patients ≥12yo with Dystrophic Epidermolysis bullosa; NEMODE

2026-526417-28-00dystrophic epidermolysis bullosa

DrugNemolizumab

Centre Hospitalier Universitaire De Nice

Skin and Connective Tissue Diseases

France

16/10/2026

Phase II

EVITA - Epcoritamab plus Venetoclax plus Ibrutinib in patients with chronic lymphocytic leukemia with TP53 Alterations

2025-520893-20-00Chronic lymphocytic leukemia, B-cell small lymphocytic lymp…

DrugsEpcoritamab·Ibrutinib·Venetoclax

LYSARC

Hemic and Lymphatic Diseases

Belgium, France

16/10/2026

Phase II

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Finding Trial to Evaluate the Efficacy and Safety of Orally Administered NS-863 in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

2025-525115-16-00Pulmonary Hypertension Associated with Interstitial Lung Di…

DrugNS-863

Ns Pharma Inc.

Respiratory Tract Diseases

Italy, Greece, Portugal, France, Belgium, Germany, Spain

16/10/2026

Phase II

A Phase 2, Open-label, Multicenter Study to Determine the Safety, Tolerability, and Efficacy of MK- 1045 in Participants with Hematologic Malignancies

2025-522242-49-00CLL/SLL

DrugsMK-1045·Tocilizumab

Merck Sharp & Dohme LLC

Neoplasms

Spain, Italy

15/10/2026

Phase II

A randomized, parallel-group, open-label, Phase IIb pilot trial to evaluate the effectiveness in reducing systemic disease activity with methotrexate compared with hydroxychloroquine in adult male and female participants with moderate-to-severe primary Sjögren’s disease (MOSAIC STUDY)

2026-526767-38-00Sjogren's disease

DrugHydroxychloroquine

Fondazione Policlinico Universitario Campus Bio-medico In Forma A Bbreviata Fon

Immune System Diseases

Italy

15/10/2026

Phase II

A Phase 2a Trial to Explore the Efficacy and Safety of OXT-328 5% Topical Gel in Patients with Chemotherapy-Induced Peripheral Neuropathy, Diabetic Peripheral Neuropathy, and Cervical Radiculopathy

2026-527437-55-00Peripheral neuropathy

Jcare Pharmaceuticals LLC

Nervous System Diseases

Greece

15/10/2026

Phase II

A randomized, double-blind, placebo-controlled, multicenter Phase 2a/b study assessing the efficacy, safety and tolerability of DDY391 in participants with Sjögren's Disease

2025-524513-92-00Sjögren's Disease

Novartis Pharma AG

Immune System Diseases

Portugal, Bulgaria, Belgium, Spain, Denmark, France, Slovakia, Poland, Hungary, Italy, Netherlands, Germany, Austria

15/10/2026

Phase II

A Placebo-Controlled, Multicenter, Randomized Phase 2 Trial Evaluating the Efficacy and Safety of Felzartamab Compared to Placebo in Adult Participants with Graves’ Disease

2026-526482-19-00Graves’ Disease

DrugFelzartamab

Biogen Idec Research Limited

Nutritional and Metabolic Diseases

Italy, Spain

15/10/2026

Phase II

Phase 2, open-label, randomized study to investigate safety and efficacy of Pluvicto® therapy in patients with metastatic hormone-sensitive prostate cancer in addition to standard of care treatment with Nubeqa® and ADT (ARALU)

2026-525520-20-00Patients with synchronous metastatic hormone-sensitive pros…

Medical Center - University Of Freiburg

Neoplasms

Germany

15/10/2026

Phase II

A Prospective, Randomized, Open-label, Multicentre Study to Compare the Safety of PURETHAL Mites Mixture 50,000 AUeq/mL Rush Up-Dosing Regimen with the Conventional Up-Dosing Regimen in Adult Participants with Allergic House Dust Mite Rhinitis/Rhinoconjunctivitis with or without Asthma

2026-526908-72-00Allergic House Dust Mite Rhinitis/Rhinoconjunctivitis with …

HAL Allergy B.V.

Immune System Diseases

Poland, Germany

14/10/2026

Phase II

A Phase 2, Multicentre, Randomised, Double-masked, Placebo-controlled, Parallel-group, Dose-range Finding Study, to Assess the Efficacy and Safety of Oral STL303 in Adults with Geographic Atrophy Secondary to Age-related Macular Degeneration

2026-525738-40-00Geographic Atrophy Secondary to Age-related Macular Degener…

DrugSTL303

Sitala Bio Limited

Eye Diseases

Poland, Czechia

14/10/2026

Phase II

Multicenter, open label, phase II clinical trial evaluating the combination of elranatamab with mezigdomide and dexamethasone in patients with relapsed/refractory multiple myeloma

2026-526352-31-00Relapsed/refractory multiple myeloma

DrugsMezigdomide·Elranatamab

Fundacion PETHEMA

Neoplasms

Spain

13/10/2026

Phase II

A single-arm pilot study to investigate tumor absorbed dose dynamics and feasibility of pre-treatment dosimetry with [177Lu]-PSMA-I&T in male participants aged ≥ 18 years with metastatic castration-resistant prostate cancer

2026-526519-12-00Metastatic castration-resistant prostate cancer

Universitetssykehuset Nord-Norge HF

Neoplasms

Norway

13/10/2026

Phase II

PRECISION Study: A phase II prospective, mono-center, randomized, double-blinded, controlled trial to assess the efficacy of local iloprost therapy to promote bone healing in patients at risk for fracture non-union

2026-527568-34-00bone fracture in patients identified as being at high risk …

DrugIloprost

Charite Universitaetsmedizin Berlin KöR

Musculoskeletal Diseases

Germany

13/10/2026

Phase II

Semaglutide for the treatment of visceral obesity in people with HIV with body mass index <30 kg/m2 and without diabetes: a randomized clinical trial to explore immune metabolism, systemic and vascular inflammation assessed with Positron Emission Tomography

2026-526738-18-00Adult subjects with HIV infection on stable antiretroviral …

DrugSemaglutide

Azienda Ospedaliero Universitaria Di Modena

Virus Diseases

Italy

12/10/2026

Phase II

A Dose-finding, Double-blind, Randomized, Placebo-controlled Phase 2 Study to Evaluate the Efficacy and Safety of Treatment with Efimosfermin Alfa in Adult Participants with Alcohol-related Liver Disease (ALD)

2026-526391-23-00Liver Diseases, Alcoholic

Glaxosmithkline Research & Development Limited

Digestive System Diseases

Spain, Denmark, Italy, Poland, France, Germany, Greece

12/10/2026

Phase II

An open label, multi-center alpelisib roll-over study to assess long-term safety in participants who have completed a Novartis sponsored alpelisib (BYL719) study and are judged by the Investigator to benefit from continued treatment with alpelisib.

2026-525890-38-00• PROS (PIK3CA‑Related Overgrowth Spectrum) and, • Breast N…

DrugsAlpelisib·Fulvestrant

Novartis Pharma AG

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

France, Italy, Bulgaria, Slovakia, Finland, Spain

12/10/2026

Phase II

HOVON 185: Pharmacokinetic boosting of ibrutinib with ritonavir in patients with chronic lymphocytic leukemia, lymphoplasmacytic- and mantle cell lymphoma

2026-526101-15-00lymphoplasmacytic lymphoma, chronic lymphocytic leukemia, m…

DrugsRitonavir·Ibrutinib

Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Hemic and Lymphatic Diseases

Netherlands

12/10/2026

Phase II

MOST-Express – A phase II, multicenter, open-label, personalized medicine, tumor agnostic platform trial evaluating the anti-tumor activity of antibody-based therapies in metastatic cancer patients.

2025-522058-38-00HER2-positive rare cancer, HER2 positive non-small cell lun…

DrugTrastuzumab deruxtecan

Centre Leon Berard

Pathological Conditions, Signs and Symptoms

France

09/10/2026

Phase II

CombiMucor - Efficacy of combination therapy with isavuconazole and intermittent high doses liposomal amphotericin B for the treatment of mucormycosis

2025-521505-40-00Adults with mucormycosis

DrugAmphotericin B

Assistance Publique Hopitaux De Paris

Bacterial Infections and Mycoses

France

09/10/2026

Phase II

ASPIRE-1; Individual and combined endothelin receptor and SGLT2 antagonism in adults with type 1 diabetes mellitus and chronic kidney disease: a Phase 2, multicenter, open-label randomized cross-over trial

2026-525684-40-01Chronic Kidney Disease, Type 1 Diabetes

DrugDapagliflozin

Universitair Medisch Centrum Groningen

Nutritional and Metabolic Diseases

Finland, Denmark

09/10/2026

Phase II

A Phase 2, multicentre, randomised, double-blind, placebo-controlled trial to evaluate the efficacy and safety of LAD603 in patients with systemic lupus erythematosus

2026-527200-24-00Systemic lupus erythematosus

Almirall S.A.

Immune System Diseases

Poland, Spain, Hungary, Bulgaria

09/10/2026

Phase II

2025-525114-38-00Pulmonary Arterial Hypertension (PAH)

DrugNS-863

Ns Pharma Inc.

Respiratory Tract Diseases

France, Germany, Poland, Italy, Belgium, Spain, Greece

08/10/2026

Phase II

Endocrinological Support Therapy After Military Operations

2026-525935-18-01The participants do not have any medical condition

DrugTestosterone Undecanoate

Norges Idrettshoegskole

Musculoskeletal and Neural Physiological Phenomena

Norway

08/10/2026

Phase II

An Exploratory Phase II, Randomized, Open-Label, Proof-of-Concept Trial Evaluating Add-on Polyunsaturated Fatty Acid Ethyl Esters on Pain and Minimal Disease Activity in Psoriatic Arthritis Patients Starting TNF-alpha Inhibitors

2026-526768-20-00Psoriatic arthritis

DrugsCertolizumab Pegol·Golimumab·Etanercept·Infliximab

Fondazione Policlinico Universitario Campus Bio-medico In Forma A Bbreviata Fon

Immune System Diseases

Italy

06/10/2026

Phase II

A Phase 2, Multicenter, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of ARGX-121 SC in Adult Participants With Primary IgA Nephropathy

2026-525638-43-00Immunoglobulin A nephropathy (IgAN)

Argenx

Not possible to specify

Spain, Poland, Czechia, Belgium, Italy

05/10/2026

Phase II

A phase 2 study to assess efficacy of induction Enfortumab Vedotin plus Pembrolizumab using a response-adapted approach to spare the bladder: FIDELIO

2026-525965-29-00Adult patients with cT2-4aN0-1 urothelial bladder cancer, w…

DrugsEnfortumab Vedotin·Pembrolizumab

Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Neoplasms

Netherlands

05/10/2026

Phase II

LIGHTBEAM-U01 Substudy 01E: A Phase 2 Substudy to Evaluate the Safety and Efficacy of Belzutifan in Participants With Solid Tumors

2025-524515-37-00Neoplasm malignant

DrugBelzutifan

Merck Sharp & Dohme LLC

Neoplasms

Belgium, Spain, Denmark, Italy, France

05/10/2026

Phase II

Breast density reduction with linzagolix or bilastine in premenopausal women at high risk of breast cancer: a phase II clinical trial.

2026-525672-26-01Increased risk of breast cancer

Consorci Mar Parc De Salut De Barcelona

Neoplasms

Spain

01/10/2026

Phase II

Hex-SUB1-IPC 2025-067 - PROOF OF CONCEPT: FEASIBILITY OF PHOTODYNAMIC DIAGNOSIS IN BLADDER CANCER PATIENTS WITH SUB-ONE-HOUR INSTILLATION TIME OF HEXAMINOLEVULINATE (HEXVIX®)

2026-526917-27-00primary or recurrent confirmed papillary bladder cancer (BC)

DrugHexvix

Institut Paoli Calmettes

Neoplasms

France

30/09/2026

Phase II

SEMAGONA: A randomized four-arm parallel group double-blind double dummy 52-week clinical trial comparing the effects of s.c. Semaglutide 2.4 mg once-weekly, i.m. testosterone undecanoate 1,000 mg every 13th week, combination of s.c. Semaglutide 2.4 mg once-weekly and i.m. testosterone undecanoate 1,000 mg every 13th week, and placebo on body composition and hypogonadal symptoms in men with obesity-associated functional hypogonadism

2026-527373-11-00Functional hypogonadism

DrugsNebido·Semaglutide

Region Hovedstaden

Hormonal diseases

Denmark

30/09/2026

Phase II

PHOENIX - ECP: A Phase 2, Randomized, Controlled, Open-label, Multicenter Study to Evaluate the Efficacy and Safety/Tolerability of Extracorporeal Photopheresis (ECP) Versus Best Available Therapy (BAT) for the Treatment of Immune-related Colitis and/or Hepatitis with Inadequate Response to Corticosteroids in Participants with Unresectable or Metastatic Melanoma Treated with Immune Checkpoint Inhibitors (ICI)

2026-526261-14-00Immune-related Colitis or Hepatitis with Inadequate Respons…

DrugsAzathioprine·Vedolizumab·Infliximab

Therakos Europe Limited

Neoplasms

Austria, Spain, Italy, Germany, Netherlands

30/09/2026

Phase II

Safety and Tolerability of systemic administration of metformin in patients with Idiopathic Pulmonary Fibrosis (IPF): A randomized, placebo-controlled, double-blind, phase II proof-of-concept study (Met_for_IPF)

2025-523341-10-00Idiopathic pulmonary fibrosis

Philipps-Universitaet Marburg

Respiratory Tract Diseases

Germany

30/09/2026

Phase II

A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety, Tolerability, and Efficacy of MZE782 in Adults with Phenylketonuria (PKU)

2026-525622-37-01Phenylketonuria

Maze Therapeutics Inc.

Nutritional and Metabolic Diseases

Germany, France, Netherlands

29/09/2026

Phase II

A Randomized, Double-Blind, Placebo-controlled, Parallel Arm, 52-week Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of Two Doses of EXPD-101 in Participants with COPD

2026-525216-34-00Chronic Obstructive Pulmonary Disease (COPD) exacerbations

Expedition Therapeutics Inc.

Respiratory Tract Diseases

Italy, Germany, Spain, Poland, Czechia, Romania, Hungary, Denmark, Bulgaria

29/09/2026

Phase II

Effects of a CB1 Receptor Antagonist/Inverse Agonist (Rimonabant) on the Improvement of Cognitive Impairment in Patients with Post-COVID-19 Syndrome (RIMOCOVID-1)

2023-507870-42-00Post-COVID-19 syndrome

DrugRimonabant

Sinfatin S.L.

Virus Diseases

Spain

28/09/2026

Phase II

FILOCLL017 - NEVOTAL : Nemtabrutinib in addition to Venetoclax-Obinutuzumab in chronic lymphocytic leukemia (CLL) / small lymphocytic leukemia (SLL) patients with TP53 ALterations

2026-525763-40-00Patients with previously untreated chronic lymphocytic leuk…

DrugsNemtabrutinib·Obinutuzumab·Venetoclax

French Innovative Leukemia Organization (F.I.L.O.).

Hemic and Lymphatic Diseases

France

25/09/2026

Phase II

A phase 2, open-label, Multicenter, Randomized study of Trastuzumab Deruxtecan versus investigator’s choice chemotherapy in recurrent ovarian cancer that progressed on prior PARP inhibitor therapy: TROY (APGOT-OV14)

2026-527010-23-00Ovarian cancer

DrugsTrastuzumab deruxtecan·Bevacizumab

Fundacion Grupo Espanol De Investigacion En Cancer Ginecologico

Neoplasms

Spain

25/09/2026

Phase II

RINGQUEST: Exploring Understudied Genitourinary Tumors with Sacituzumab Tirumotecan; a Single-arm, Basket, Phase II Study.

2026-526048-10-00Papillary Renal Cell Carcinoma (pRCC) Variant Histology Uro…

DrugSacituzumab tirumotecan

Alianza Multidisciplinar Para La Investigacion De Los Tumores Genitourinarios Guard

Neoplasms

Spain

24/09/2026

Phase II

A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Efficacy and Safety of Nalbuphine Extended-Release Tablets for the Treatment of Participants with Refractory Chronic Cough

2026-526087-20-00Refractory Chronic Cough

DrugNalbuphine

Trevi Therapeutics Inc.

Respiratory Tract Diseases

Poland

24/09/2026

Phase II

A Phase 2b, Double-Blind, Placebo-Controlled, Multicenter Proof of Concept Clinical Study to Evaluate the Efficacy and Safety of ATH-063 Induction Therapy in Patients with Biologic Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis (UC)

2024-520183-33-00Active Ulcerative Colitis

Athos Therapeutics Inc.

Digestive System Diseases

Poland

24/09/2026

Phase II

OASIS-ImmunoPET_Antibody-based PET imaging and treatment response in breast cancer treated with an antibody-drug conjugate according to current standard indications.

2025-524369-26-00Patients with histologically confirmed or radiologically do…

Unicancer

Neoplasms

Belgium

23/09/2026

Phase II

Use of the Checkpoint inhibitor DOstarlimab in the endOmetrial cancer fertility-Sparing trEatment: CHOOSE study.

2023-509535-11-00Newly diagnosed endometrial carcinomas of the MMR-deficient…

DrugDostarlimab

UZ Leuven

Neoplasms

Italy, Belgium

23/09/2026

Phase II

An Open-Label Phase 2a Study to Evaluate the Safety, Tolerability, and Efficacy of Vafidemstat in Adults with Phelan-McDermid Syndrome (PMS) (HOPE-2).

2026-525699-24-00Phelan McDermid Syndrome

Oryzon Genomics S.A.

Behavior and Behavior Mechanisms

Spain

23/09/2026

Phase II

A Phase 2b, Randomized, Placebo-controlled, Double-blind, Dose-ranging Trial to Assess the Efficacy and Safety of Ontunisertib in Patients with Fibrostenosing Crohn’s Disease

2026-525197-19-00Fibrostenosing Crohn’s Disease

DrugOntunisertib

Agomab Spain S.L.U.

Digestive System Diseases

France, Germany, Poland, Spain, Czechia, Denmark, Austria, Italy, Belgium, Netherlands

21/09/2026

Phase II

Learning From Early Aficamten In HCM (LEAF-HCM)

2025-523090-42-00Hypertrophic cardiomyopathy

DrugsAficamten·[68Ga]Ga-FAPI-46

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Cardiovascular Diseases

Netherlands

21/09/2026

Phase II

A Phase 2b, randomized, placebo-controlled, observer-blind study in adults 60 years and older to evaluate the efficacy, safety, and immunogenicity of a bivalent protein vaccine candidate against Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (HMPV)

2026-526177-42-00Infections and infestations

Sanofi Vaccines US Inc.

Virus Diseases

Estonia, Spain, Germany, Czechia, Poland, Finland, Netherlands

21/09/2026

Phase II

A Multicenter, Open-Label, Phase II Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years of Age with Systemic Lupus Erythematosus.

2025-524578-41-00Systemic Lupus Erythematosus

DrugAnifrolumab

AstraZeneca AB

Immune System Diseases

Belgium, Portugal, Netherlands

21/09/2026

Phase II

An Open-label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of ORKA-001 in Participants with Moderate-to-Severe Plaque Psoriasis

2026-526898-42-00Moderate-to-Severe Plaque Psoriasis

DrugORKA-001

Oruka Therapeutics Inc.

Skin and Connective Tissue Diseases

Spain, Germany

21/09/2026

Phase II

Randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the safety and efficacy of 2 dose levels of the oral ghrelin receptor agonist AC01 over 12 weeks in patients with chronic advanced heart failure with reduced ejection fraction (HFrEF)

2025-524469-25-00chronic advanced heart failure with reduced ejection fracti…

AnaCardio AB

Cardiovascular Diseases

Czechia, Slovakia, Spain, Bulgaria, Netherlands, Italy, Poland, Germany, Sweden, Hungary

21/09/2026

Phase II

A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Moderate to Severe Atopic Dermatitis (SIERRA1)

2025-524384-20-00Atopic dermatitis (AD)

DrugSoquelitinib

Corvus Pharmaceuticals Inc.

Skin and Connective Tissue Diseases

Italy, Czechia, Germany, Poland, Spain, Bulgaria

18/09/2026

Phase II

Prevention of venous thromboembolism in cirrhotic patients with hepatocellular carcinoma

2026-526857-33-00liver cirrhosis and hepatocellular carcinoma

DrugTinzaparin

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Neoplasms

Italy

17/09/2026

Phase II

BASTION – Phase II Trial of BrECADD in HIV-Positive Patients with Advanced-Stage Classic Hodgkin Lymphoma

2025-521749-26-00Advanced Stage Classic Hodgkin Lymphoma

DrugsBrentuximab Vedotin·Dacarbazine·Doxorubicin·Etoposide

University Of Cologne

Hemic and Lymphatic Diseases

Germany

17/09/2026

Phase II

The Role of Serotonin 4 Receptor Agonism in Regulating Mood and Cognition in Depression in women (RECAP-D)

2026-526685-25-00Major depressive disorder

DrugsPrucalopride·Sertraline

Region Hovedstaden

Mental Disorders

Denmark

17/09/2026

Phase II

A phase II randomised trial investigating the benefit of adjuvant immunotherapy after neoadjuvant chemoimmunotherapy for resectable NSCLC (ADIL)

2025-524439-38-00Non Small Cell Lung Cancer (NSCLC)

DrugDurvalumab

Oslo Universitetssykehus HF

Respiratory Tract Diseases

Sweden, Norway, Denmark

16/09/2026

Phase II

A single-centre, Phase 2, open-label study to investigate ovulation inhibition after the administration of different dosages of dienogest tablets in combination with different dosages of drospirenone tablets with regular intake and after intentional intake errors in healthy premenopausal female participants

2026-526788-39-00Contraception/Pregnancy prevention in healthy subjects

Gedeon Richter Plc.

Reproductive and Urinary Physiological Phenomena

Germany

16/09/2026

Phase II

A Phase II, randomized, blinded, dose selection study to assess safety and preliminary efficacy of antithrombotic heparin proteoglycan mimetic APAC (antiplatelet, anticoagulant) administered locally to the site of arterio-venous fistula (AVF) surgery to facilitate maturation of hemodialysis (HD) vascular access in patients with end stage kidney disease (ESKD) (MATURATION)

2026-526207-30-00End stage kindey disease

DrugHeparin

Aplagon Oy

Not possible to specify

Sweden, Spain, Finland

15/09/2026

Phase II

Multicenter, open label, phase II clinical trial of inotuzumab ozogamicin as prophylaxis for relapse in patients with high-risk acute B-cell precursor acute lymphoblastic leukaemia after allogeneic stem cell haemotopoietic transplantation

2026-525964-17-00Acute lymphoblastic leukaemia

DrugInotuzumab Ozogamicin

Fundacion PETHEMA

Neoplasms

Spain

15/09/2026

Phase II

J2S-MC-GZMV: A Phase 2, Multicenter, Randomized, Double-Blind, 52-week Study to Investigate the Efficacy and Safety of Brenipatide Compared With Placebo for the Treatment of Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

2026-525480-41-00Pulmonary Disease, Chronic Obstructive

DrugBrenipatide

Eli Lilly & Co.

Respiratory Tract Diseases

Denmark, France, Romania, Czechia, Poland, Hungary, Germany, Austria

15/09/2026

Phase II

Interventional, randomized, double-blind, parallel-group, placebo-controlled, flexible-dose trial of Lu AF28996 in adults with Parkinson’s disease experiencing motor fluctuations.

2025-524655-30-00Parkinson’s disease

H. Lundbeck A/S

Nervous System Diseases

Czechia, France, Spain, Poland, Italy, Germany, Sweden

15/09/2026

Phase II

Optimization of De-EscalatiON strategies in early breast cancer

2026-527524-27-00breast cancer

DrugsTrastuzumab emtansine·Exemestane·Anastrozole·Ribociclib

Istituto Di Candiolo Fondazione Del Piemonte Per L'Oncologia IRCCS

Neoplasms

Italy

14/09/2026

Phase II

A multicenter, randomized, double-blind, placebo- controlled Phase 2 study to investigate the efficacy, safety and tolerability of remibrutinib (LOU064) in adult patients with Papulopustular Rosacea (PPR)

2025-524496-23-00Papulopustular Rosacea (PPR)

Novartis Pharma AG

Skin and Connective Tissue Diseases

Bulgaria, Spain, France, Italy, Germany

14/09/2026

Phase II

COLIBRI-GI_Randomized phase 2 study of second-line chemotherapy comparing FOLFIRI + ivonescimab versus FOLFIRI + bevacizumab in Microsatellite Stable (MSS)/ proficient MisMatch Repair (pMMR) BRAF wild type (wt) advanced colorectal cancer (mCRC) without liver metastases

2025-524215-36-00Patients with non resectable pMMR/MSS BRAF wt mCRC, without…

DrugsFolinic acid·Ivonescimab·Fluorouracil·Leucovorin

Unicancer

Neoplasms

France

11/09/2026

Phase II

Attenuating Calciprotein particles Transformation and Inhibiting Vascular calcification Evolution by Sodium ThioSulphate trial

2026-525680-41-00Vascular Calcification

Radboud universitair medisch centrum Stichting

Therapeutics

Netherlands

11/09/2026

Phase II

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adult Participants with Moderate-to-Severe Atopic Dermatitis

2026-526184-38-00Atopic Dermatitis

DrugENV-294

Enveda Therapeutics Inc.

Skin and Connective Tissue Diseases

Germany, Czechia, Bulgaria, Poland, Spain

10/09/2026

Phase II

Pilot study with Low-dose nivolumab in Advanced Neoplasms that are TMB-high

2026-525445-73-00TMB-high advanced neoplasms

DrugNivolumab

UZ Brussel

Neoplasms

Belgium

09/09/2026

Phase II

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Semaglutide Subcutaneous Depot (CAM2056) in People with Obesity or Overweight

2026-526951-79-00Body weight management

Camurus AB

Nutritional and Metabolic Diseases

Germany

09/09/2026

Phase II

A Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long Term Safety and Tolerability of KT-621 in Participants With Asthma Previously Enrolled in a KT-621 Asthma Study

2026-526241-98-00Uncontrolled Moderate to Severe Eosinophilic Asthma

DrugKT-621

Kymera Therapeutics Inc.

Immune System Diseases

Austria, Germany, Belgium, Romania, Italy, Slovakia, Poland, Spain

09/09/2026

Phase II

A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Participants with Sjogren’s Disease-Associated Sensorimotor or Sensory Polyneuropathy

2026-526218-10-00Sjogren’s Disease-Associated Sensorimotor Polyneuropathy (S…

Argenx

Immune System Diseases

Germany, Estonia, Lithuania, Portugal, Slovakia, Hungary, Romania, Poland, Spain, Austria, Belgium, France, Bulgaria

08/09/2026

Phase II

SemenGlutide: A randomized double-blinded, placebo-controlled, single-center, clinical trial comparing the effects of s.c. Semaglutide 2.4 mg once-weekly versus placebo on sperm concentration in overweight infertile men

2026-527538-29-00Infertility, overweight

DrugSemaglutide

Region Hovedstaden

Male Urogenital Diseases

Denmark

08/09/2026

Phase II

Effects of semaglutide as add-on therapy to sulfonylurea on plasma glucose in individuals with HNF1A- and HNF4A-MODY – A Steno MODERN-MODY project (MM-SEMA)

2025-523414-89-00Maturity-onset diabetes of the young type 3 (HNF1A-MODY), M…

DrugSemaglutide

Steno Diabetes Center Copenhagen

Hormonal diseases

Denmark

08/09/2026

Phase II

A Phase 2, Randomized, Open-label, Study Assessing the Safety, Tolerability and Efficacy of Imzokitug in Combination with Pumitamig and Platinum-Doublet Chemotherapy (PDCT) versus Pumitamig and PDCT as First-line Treatment for Participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

2026-525170-19-00Locally Advanced or Metastatic Non-Small Cell Lung Cancer (…

Bristol-Myers Squibb Services Unlimited Company

Neoplasms

Italy, Spain, Romania, Germany, France

07/09/2026

Phase II

"Evaluation of the impact of the dose of heparin on the occurrence of DWI ischemic lesions after embolization of unruptured intracranial aneurysm" "HARMONI"

2026-526530-13-00Intracranial aneurysms

DrugsAcetylsalicylic acid·Ticagrelor

Centre Hospitalier Universitaire De Bordeaux

Nervous System Diseases

France

07/09/2026

Phase II

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of NBI-1065890 in Adult Participants With Tardive Dyskinesia

2025-524104-30-00Tardive Dyskinesia

Neurocrine Biosciences Inc.

Nervous System Diseases

Bulgaria, Croatia, Romania, Slovakia, Czechia

07/09/2026

Phase II

A Multicenter, Open-Label, Single-Group Clinical Study to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab in Pediatric Subjects (aged 6 to 23 months) with Moderate-to-Severe Atopic Dermatitis Not Adequately Controlled with Topical Therapy

2025-525027-27-00Atopic Dermatitis

Galderma S.A.

Skin and Connective Tissue Diseases

Poland

04/09/2026

Phase II

Randomized, Double blind, Phase II Trial of Vortosiran to Evaluate Safety, Tolerability, and Pharmacodynamic Efficacy in Participants with Prior Venous Thromboembolism After Completion of Initial Anticoagulant Therapy (Cohort A) and in Cancer Patients at High Risk of Venous Thromboembolism (Cohort B)

2026-525479-15-00Venous Thromboembolism

DrugRBD4059

Ribocure Pharmaceuticals AB

Cardiovascular Diseases

Poland, Romania, France, Bulgaria

04/09/2026

Phase II

BiFAST : A phase II trial evaluating fixed dose and faster ramp-up of epcoritamab with lenalidomide for 3L relapse/refractory large B-cell lymphoma after CAR T-cells therapy in 2nd line

2025-520895-24-003L relapse/refractory large B-cell lymphoma after CAR T-cel…

DrugsEpcoritamab·Lenalidomide

LYSARC

Hemic and Lymphatic Diseases

France

02/09/2026

Phase II

Hyperthermic Intraperitoneal Chemotherapy and Regional Adrenalectomy in the management of Stage II & III Adrenocortical Carcinoma

2026-525406-36-00Adrenocortical Carcinoma

DrugsSodium Thiosulfate·Doxorubicin·Cisplatin

Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia

Neoplasms

Italy

02/09/2026

Phase II

Propranolol Dosefinding Assessment in Reactive Aggression Treatment (PRO-DART)

2026-526545-95-00Reactive aggression

DrugPropranolol

Radboud universitair medisch centrum Stichting

Behavior and Behavior Mechanisms

Netherlands

02/09/2026

Phase II

A phase II, open-label, randomized, multi-center study comparing the efficacy and safety of Sacituzumab govitecan versus investigator's choice in patients with cancer of unknown primary (CUP) who are relapsed after or refractory to platinum-based chemotherapy (SACICUP)

2025-523055-55-00Neoplasm

DrugsCalcium folinate·Sacituzumab Govitecan·Fluorouracil·Docetaxel

Universitaetsklinikum Heidelberg AöR

Neoplasms

Germany

01/09/2026

Phase II

Randomized, Multicenter, Vehicle-Controlled, Double-Masked Study to Evaluate the Efficacy and Safety of Intranasal Cenegermin (Recombinant Human Nerve Growth Factor [rhNGF]) in Adult Participants with Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)

2025-524748-37-00Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)

DrugCenegermin

Dompe' Farmaceutici S.p.A.

Eye Diseases

Denmark, Italy, Germany, Hungary, Netherlands, Spain, Belgium, France, Portugal

01/09/2026

Phase II

A multicenter, prospective, randomized, placebo and non-surgical standard of care (NSSOC) controlled study, performed to evaluate the safety and efficacy of EscharEx and its placebo (gel vehicle) compared to NSSOC in participants with Venous Leg Ulcers (VLU)

2026-526070-16-00Venous Leg Ulcer (VLU)

DrugEscharEx

Mediwound Ltd.

Skin and Connective Tissue Diseases

Czechia, Slovakia

01/09/2026

Phase II

A phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of VQ-101 in participants with Parkinson’s disease carrying a heterozygous mutation of GBA1

2026-525848-15-00GBA1-associated Parkinson’s disease

Vanqua Bio Inc.

Nervous System Diseases

Netherlands, France, Spain, Germany

01/09/2026

Phase II

Clinical Study of Local and Systemic biological Impact of GLP1/GIP-Receptor Agonists in patients with Breast Cancer: The CLARA trial

2026-525820-76-00Hormone Receptor positive postmenopausal breast cancer

DrugsTirzepatide·Letrozole

UZ Leuven

Neoplasms

Belgium

31/08/2026

Phase II

A Phase II, single-arm trial on the addition of the DLL3xCD3 bispecific T-cell engager obrixtamig (BI 764532) to standard-of-care platinum-based first-line treatment of advanced large-cell neuroendocrine carcinoma of the lung (ALPINE 2)

2025-524345-28-00Male and female adult patients with locally advanced or met…

DrugObrixtamig

Technische Universitaet Dresden

Neoplasms

Germany

31/08/2026

Phase II

In-vivo fluorescence molecular bronchoscopy of durvalumab-680LT in patients with unresectable stage III NSCLC after chemoradiation - PulmoPrint

2026-526251-60-00Unresectable stage III non-small cell lung cancer

DrugDurvalumab

Universitair Medisch Centrum Groningen

Neoplasms

Netherlands

31/08/2026

Phase II

HOVON 168: Epcoritamab in Addition to R-Mini-CHOP Compared to R-Mini-CHOP in Elderly, Frail or Unfit Patients with Diffuse Large B-cell Lymphoma

2025-524230-25-00Diffuse large B-cell lymphoma (DLBCL)

DrugsEpcoritamab·Rituximab

Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Hemic and Lymphatic Diseases

Czechia, Denmark, Croatia, Spain, Sweden, Finland, Portugal, Ireland, Netherlands, Belgium, Norway

31/08/2026

Phase II

Targeting IL-13 in Bullous Pemphigoid: An Investigator-Initiated, Prospective, Multicenter, Proof-of-Concept, Open-Label Pilot Study of Lebrikizumab

2026-525685-22-00Bullous pemphigoid

DrugLebrikizumab

Region Midtjylland, Region Sjaelland

Immune System Diseases

Denmark

31/08/2026

Phase II

Efficacy and safety of once-weekly subcutaneous UBT251 in participants with type 2 diabetes – a dose-finding study

2026-525465-42-00Type 2 diabetes (T2D)

Novo Nordisk A/S

Nutritional and Metabolic Diseases

Spain, Hungary, Romania, Slovakia, Poland, Germany

31/08/2026

Phase II

Paediatric sarcoma, hybrid imaging & FAPI – Raising the diagnostic standard for paediatric sarcoma patients combining novel radiotracer FAPI and whole-body PET/MRI

2025-524874-41-00Paediatric sarcoma

Drug[68Ga]Ga-FAPI-46

Rigshospitalet

Diagnosis

Denmark

28/08/2026

Phase II

MDMA-assisted therapy for adolescents with treatment-resistant PTSD

2024-515184-65-01Post-traumatic stress disorder

Stichting Amsterdam UMC

Mental Disorders

Netherlands

26/08/2026

Phase II

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Oral PIPE-791 in Subjects with Idiopathic Pulmonary Fibrosis

2025-521901-42-00Idiopathic Pulmonary Fibrosis (IPF)

Contineum Therapeutics Inc.

Respiratory Tract Diseases

Italy, Belgium, Denmark, Austria, Greece, Germany, France, Netherlands, Portugal, Poland, Spain

26/08/2026

Phase II

C6461010 - An Interventional, Open-Label, Phase 2 Study to Investigate the Safety and Efficacy of PF-08634404 Monotherapy or in Combination in Adult Participants with Early-Stage Resectable or Locally Advanced Unresectable Non-Small Cell Lung Cancer

2025-524825-42-00Early-Stage Resectable or Locally Advanced Unresectable Non…

Pfizer Inc.

Neoplasms

Spain, France, Italy, Ireland, Germany, Poland

26/08/2026

Phase II

A Phase 2, Open-label, Multicohort, Study of Rinatabart Sesutecan (Rina S) in Participants With Advanced Gastrointestinal (GI) Cancers

2025-524130-26-00Gastrointestinal Cancers

Genmab A/S

Neoplasms

Italy, Belgium, France, Spain, Denmark, Netherlands, Germany

26/08/2026

Phase II

Development of a Short-Acting GH Suppression Test with subcutaneous short action Pasireotide (PAT) for Predicting Long-Term Response to Pasireotide LAR in Patients with Acromegaly

2025-524253-14-00Acromegaly

Instituto De Investigacion En Ciencias De La Salud Germans Trias I Pujol

Hormonal diseases

Spain

26/08/2026

Phase II

A Phase 2a, proof-of-concept, multicenter, double-blind, randomized, placebo-controlled, parallel-group trial to assess the efficacy and safety of ACT-777991 in adults with non-segmental vitiligo

2025-524865-25-00Non-segmental vitiligo

Idorsia Pharmaceuticals Ltd.

Skin and Connective Tissue Diseases

Czechia, Poland

26/08/2026

Phase II

DIRECTION- Discontinuation versus continuation of riociguat monotherapy in chronic thromboembolic pulmonary hypertension successfully treated with balloon pulmonary angioplasty

2026-525351-81-00chronic thromboembolic pulmonary hypertension

DrugRiociguat

Assistance Publique Hopitaux De Paris

Cardiovascular Diseases

France

25/08/2026

Phase II

A Phase 2b, Randomized, Multicenter, Double-Blind, Dose-Finding, Active-Controlled Study of Siplizumab (TCD601) Compared to Rabbit Anti-Thymocyte Globulin in Renal Transplant Recipients Requiring Induction Therapy and Receiving Standard of Care Immunosuppression with Tacrolimus, Mycophenolic Acid and Corticosteroids (MODERNIZE 1)

2026-525646-29-00Renal Transplantation

DrugSiplizumab

Nefro Avillion Clinical Development LLC

Immune system processes

Czechia, Spain, Portugal, Austria

25/08/2026

Phase II

[68]GA-FAPI-46 PET/CT for the diagnosis of metastatic lesions in patients with lobular breast cancer (ICL). FAPICL

2025-524897-40-00invasive lobular carcinomas of the breast

Drug[68Ga]Ga-FAPI-46

Hospices Civils De Lyon

Diagnosis

France

25/08/2026

Phase II

A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Camoteskimab in Adults with Moderate-to-Severe Atopic Dermatitis

2026-525673-39-00Atopic Dermatitis (AD)

Apollo Therapeutics Limited

Skin and Connective Tissue Diseases

Hungary, Czechia, Germany, Bulgaria, Poland, Spain

25/08/2026

Phase II

Solid tumor Study for Long term Treatment of Cancer Patients Who Have Participated in BMS-Parent Studies Investigating Adagrasib (BMS-986503)

2025-524905-34-00Solid tumor

Bristol-Myers Squibb Services Unlimited Company

Neoplasms

Greece, Hungary, Poland, Belgium, Spain, Netherlands, Germany, France, Portugal, Italy, Romania

25/08/2026

Phase II

A Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Potential Antiseizure Activity of Adjunctive OV329 Therapy in Adults with Drug-Resistant Focal Epilepsy

2026-525896-23-00Focal epilepsy

Ovid Therapeutics Inc.

Nervous System Diseases

Netherlands

21/08/2026

Phase II

Èn dosis intravenøs penicillin som tillæg til peroral penicillin i behandlingen af akut tonsillitis, peritonsillær phlegmone og peritonsillær absces – et randomiseret, dobbeltblindet, placebo-kontrolleret studie

2026-526903-31-00Tonsillitis

DrugBenzylpenicillin

Region Midtjylland

Bacterial Infections and Mycoses

Denmark

21/08/2026

Phase II

A Randomized, Double-Blind, Phase 2 Trial Evaluating the Efficacy, Safety and Tolerability of Primary Cardioprotection with Dapagliflozin in Patients with Newly Diagnosed Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation

2026-525418-67-00Multiple Myeloma

DrugDapagliflozin

Instytut Hematologii I Transfuzjologii

Hemic and Lymphatic Diseases

Poland

21/08/2026

Phase II

Treatment of post-traumatic stress disorder with medical nitrous oxide combined with exposure to a personal traumatic script: a multicenter randomized controlled trial (POTESTA)

2026-525826-39-00Post-Traumatic Stress Disorder

Centre Hospitalier Regional Universitaire De Tours

Mental Disorders

France

19/08/2026

Phase II

A Randomized, Double-Blind, Placebo-Controlled Phase II Trial to Evaluate Safety, and Pharmacodynamics of Repeated Subcutaneously Administered RBD1119 in Participants with CAD

2026-525901-10-00Coronary artery disease

Ribocure Pharmaceuticals AB

Cardiovascular Diseases

Sweden, Poland

18/08/2026

Phase II

A Phase II, Randomized, Open-label, Multi-center Study of AK104 in Combination with Lenvatinib versus Lenvatinib in Participants with Advanced Hepatocellular Carcinoma Who Have Progressed on Atezolizumab and Bevacizumab

2025-524591-30-00Hepatocellular Carcinoma

Akeso Biopharma Co. Ltd.

Neoplasms

Poland, France, Spain, Italy

18/08/2026

Phase II

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-7262 as Monotherapy and when Coadministered with Enlicitide Decanoate in Adults With Elevated Lipoprotein(a)

2025-525102-38-00Elevated lipoprotein(a)

Merck Sharp & Dohme LLC

Cardiovascular Diseases

Netherlands, Denmark, Germany, Spain

18/08/2026

Phase II

A Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 48-week SAR448851 treatment followed by open-label extension in participants with early Alzheimer’s disease.

2025-524581-14-00Dementia Alzheimer's type

Sanofi-Aventis Recherche & Developpement

Nervous System Diseases

Spain, Germany

18/08/2026

Phase II

FLUDARABINE-TREOSULFAN REDUCED INTENSITY CONDITIONING REGIMEN PRIOR HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST TRANSPLANTATION CYCLOPHOSPHAMIDE FOR OLDER AND/OR FRAIL PATIENTS WITH AML

2025-523632-39-00acute myeloid lymphoma

DrugsCiclosporin·Treosulfan·Mycophenolate Mofetil·Fludarabine

Institut Paoli Calmettes

Neoplasms

France

17/08/2026

Phase II

Efficacy of rituximab for remission maintenance in patients with primary angiitis of the central nervous system: an open-label, randomized, controlled trial comparing systematic rituximab infusions and azathioprine - MAINRIPAC

2026-525394-39-00Patients with primary angiitis of the central nervous system

DrugsAzathioprine·Rituximab

Groupe Hospitalier Universitaire Paris Psychiatrie Et Neuroscience

Nervous System Diseases

France

17/08/2026

Phase II

Effects of a CB1 Receptor Antagonist/Inverse Agonist (Rimonabant) on Walking Ability in Patients in the Chronic Phase of Stroke

2025-521693-33-00Stroke

Sinfatin S.L.

Nervous System Diseases

Spain

17/08/2026

Phase II

A phase IIa open-label dose-finding study with lead-in phase evaluating the safety, pharmacokinetics, and attenuating effects of trazodone on the consciousness-altering effects of psilocybin in individuals with Treatment-Resistant Depression

2025-523346-27-00Treatment-Resistant Depression

Universita' Degli Studi G. D'Annunzio Di Chieti

Mental Disorders

Italy

14/08/2026

Phase II

Denosumab or Zoledronic acid for erosive hand osteoarthritis (EHOA) in patients with osteoporosis a randomized controlled trial (ZODIAC trial)

2026-526828-41-00Erosive hand osteoarthritis (EHOA)

DrugsZoledronic Acid·Denosumab

Azienda Ospedaliera Universitaria Integrata Verona

Musculoskeletal Diseases

Italy

14/08/2026

Phase II

A Phase 2, randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of CRD-4730 in patients with heart failure with reduced ejection fraction (HFREF) (CALIBRATE-HF)

2025-525033-31-00heart failure

DrugCRD-4730

Cardurion Pharmaceuticals Inc.

Cardiovascular Diseases

Latvia, Slovakia, Lithuania, Hungary, Italy, Netherlands, Spain, Poland, Bulgaria, Czechia

14/08/2026

Phase II

A Phase 2 Randomized Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Three Doses of Frevecitinib (KN-002) in Patients with Severe Asthma not Adequately Controlled with Medium to High Dose ICS/LABA Therapy (PANAIRAMA)

2023-509125-41-00Severe asthma

DrugSalbutamol

Kinaset Therapeutics Inc.

Respiratory Tract Diseases

Czechia, Bulgaria, Romania, Hungary, Germany, Poland, Greece

14/08/2026

Phase II

An Exploratory Phase 2 Multicenter, Double-blind, Randomized, Placebo controlled, Parallel Group Study to Investigate the Safety, Tolerability, and Efficacy of TML-6 in Early Alzheimer’s Disease

2026-525539-18-00Early Alzheimer’s Disease

Merry Life Biomedical Co. Ltd.

Nervous System Diseases

Sweden

14/08/2026

Phase II

TIPS : Immunomodulatory Treatment of Interstitial Lung Disease Associated with Surfactant related Gene Mutations

2026-525336-41-00Interstitial Lung Disease

DrugsAzithromycin·Hydroxychloroquine·Prednisolone·Prednisone

Assistance Publique Hopitaux De Paris

Respiratory Tract Diseases

France

14/08/2026

Phase II

[⁶⁸Ga]Ga-HKG301 PET/CT for staging and restaging patients with primary breast cancer: a phase II study (FAPILOUS)

2025-521324-29-00Primary breast cancer

DrugAAA514

Odense University Hospital

Neoplasms

Denmark

14/08/2026

Phase II

Quantitative Unified Assessment of Novel Triplet therapy and Unconventional Maintenance with Radium-223 for High-Volume Metastatic Hormone Sensitive Prostate Cancer: A Phase II Pilot Trial

2026-525550-11-00Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

DrugXofigo

Alianza Multidisciplinar Para La Investigacion De Los Tumores Genitourinarios Guard

Male Urogenital Diseases

Spain

14/08/2026

Phase II

Multicenter, randomized, open-label non-inferiority trial, comparing two antibiotic therapy periods (3 versus 7 days) in patients with mild leptospirosis and seen at the hospital in 5 French overseas departments (Martinique, Guadeloupe, French Guiana, Reunion, Mayotte)

2024-518027-30-00leptospirosis

DrugDoxycycline

CHU De Martinique

Bacterial Infections and Mycoses

France

13/08/2026

Phase II

A TWO-STAGE, SINGLE-ARM, PHASE II STUDY OF ZONGERTINIB PLUS FULVESTRANT IN PARTICIPANTS WITH HORMONE RECEPTOR-POSITIVE/HER2-NEGATIVE ADVANCED BREAST CANCER HARBORING HER2 MUTATIONS (AGATHA)

2026-525328-10-00HR-positive/HER2-negative advanced breast cancer

DrugsZongertinib·Goserelin·Fulvestrant

Medica Scientia Innovation Research S.L.

Neoplasms

Spain, Italy, Germany

13/08/2026

Phase II

AN OPEN LABEL, SINGLE ARM, EXPLORATIVE TRIAL TO EVALUATE EFFICACY AND SAFETY OF BEROTRALSTAT IN PREVENTING ANGIOEDEMA ATTACKS IN SUBJECTS WITH ACQUIRED ANGIOEDEMA DUE TO C1 INHIBITOR DEFICIENCY (AAE)

2025-524747-13-00Acquired angioedema due to C1 inhibitor deficiency

Policlinico San Donato S.p.A.

Genetic Phenomena

Italy

12/08/2026

Phase II

A RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, CLINICAL TRIAL OF COLCHICINE IN AMYOTROPHIC LATERAL SCLEROSIS (CO-ALS II)

2026-526460-20-00AMYOTROPHIC LATERAL SCLEROSIS

Azienda Ospedaliero Universitaria Di Modena

Musculoskeletal Diseases

Italy

12/08/2026

Phase II

A phase II, single arm two-phase, clinical study of individually adapted systemic radioligand therapy with 177Lu-PSMA I&T for patients with metastatic, castration-resistant prostate cancer

2026-527110-23-00Prostate cancer

Region Uppsala

Male Urogenital Diseases

Sweden

12/08/2026

Phase II

Evaluation of the efficacy, safety, and tolerability of lutetium-177-labeled PSMA ligand in patients with progression of adenoid cystic carcinoma originating from the salivary glands - an open, non-commercial clinical trial

2026-525776-26-00adenoid cystic carcinoma of the salivary glands

Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy

Otorhinolaryngologic Diseases

Poland

12/08/2026

Phase II

Valproic acid and lenvatinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma

2026-525733-24-00Recurrent and/or Metastatic Adenoid Cystic Carcinom

DrugsSodium valproate·Lenvatinib

Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia

Neoplasms

Italy

11/08/2026

Phase II

SDH-FLUX - Development of a new biomarker for tumor development in patients with SDHx mutation by in vivo fluxomics

2023-506001-19-00paraganglioma or pheochromocytoma with surgical indication

Assistance Publique Hopitaux De Paris

Hormonal diseases

France

10/08/2026

Phase II

A Phase 2 Multicentric Randomized Double-Blinded Efficacy and Safety Clinical Trial Comparing Several Doses of Aganirsen Eye Drops Emulsion to Extend Intravitreal Aflibercept Treatment Interval in Wet Age-Related Macular Degeneration (wAMD) Patients - SKY2 Study

2026-526775-27-00Wet Age-Related Macular Degeneration (wAMD) Patients

DrugAflibercept

Laboratoires Kol

Eye Diseases

France

10/08/2026

Phase II

Effects of a CB1 Antagonist/Reverse Agonist (Rimonabant) on Functional Recovery in Stroke Patients During Subacute Phase.

2025-521689-86-00Stroke

Sinfatin S.L.

Nervous System Diseases

Spain

10/08/2026

Phase II

A Phase 2, Multicenter, Open-Label Study of Zolacabtagene Autoleucel (BMS-986353), CD19-Targeted NEX-T CAR T Cells, in Participants with Chronic Immune Thrombocytopenia (cITP) and Autoimmune Hemolytic Anemia (AIHA) (Breakfree-AiCE)

2025-524993-41-00Chronic Immune Thrombocytopenia (cITP) and Autoimmune Hemol…

Celgene Corp.

Immune System Diseases

Germany, Denmark

10/08/2026

Phase II

An Investigator-Initiated, Descriptive, Proof-of-Concept, Open-Label Pilot Study Focusing on Topical JAK Inhibition as a Novel Treatment of Cutaneous T-Cell Lymphoma

2025-523472-23-01Cutaneous T-cell lymphoma (CTCL) Mycosis fungoides

DrugDelgocitinib

Region Midtjylland

Therapeutics

Denmark

10/08/2026

Phase II

[22961] A placebo-controlled, parallel-group, double blind, randomized, multi-cohort Phase 2 study to investigate efficacy, safety, tolerability, pharmacodynamics and pharmacokinetics of BAY 3670549 in adult participants with atrial fibrillation.

2025-523807-31-00Atrial fibrillation

Bayer AG

Cardiovascular Diseases

Belgium, Netherlands, Germany, Poland, Italy, Hungary, Bulgaria

06/08/2026

Phase II

VIP-1 : Preclinical type 1 diabetes: the VIP-1 Study

2025-524318-27-00People with stage 1 or stage 2 T1D between the ages of 7 an…

DrugVerapamil

Assistance Publique Hopitaux De Paris

Immune System Diseases

France

05/08/2026

Phase II

A Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study of YMI024 to assess efficacy in reducing inflammatory markers, safety, and tolerability in adults with stable coronary artery disease and elevated hsCRP

2026-525974-21-00Chronic Kidney Disease, Heart Failure, Coronary Artery dise…

Novartis Pharma AG

Cardiovascular Diseases

Germany

05/08/2026

Phase II

A Phase IIb Study to Evaluate the Efficacy, Safety, and Tolerability of AZD8965 in Participants with Idiopathic Pulmonary Fibrosis (IPF)) (ARGiNAUT)

2025-525016-41-00Idiopathic Pulmonary Fibrosis

AstraZeneca AB

Respiratory Tract Diseases

Poland, Hungary, Netherlands, Germany, Spain, Greece, Bulgaria, Italy, France, Denmark

04/08/2026

Phase II

Pharmacodynamic Evaluation of OV329 in Participants with Epilepsy and a Photo-Induced Generalized Epileptiform EEG-Response Phase 2 Proof-of-Concept.

2026-527114-23-00Epilepsy

Ovid Therapeutics Inc.

Nervous System Diseases

Netherlands

03/08/2026

Phase II

Botulinum toxin A in the Treatment of Chronic Postsurgical Pain in Lung Cancer Patients: A feasibility study

2026-525669-33-00Chronic postsurgical pain (CPSP)

DrugXeomin

Aalborg University Hospital

Therapeutics

Denmark

01/08/2026

Phase II

The Danish Anorexia Nervosa Psilocybin RCT (DANP-RCT). A Randomised, Active-Placebo-Controlled, Triple-blind, Superiority Study of Psilocybin-Assisted Acceptance and Commitment Therapy (ACT) in the Treatment of Treatment-resistant Anorexia Nervosa.

2025-524939-39-02Anorexia nervosa

DrugPsilocybin

Slagelse Hospital

Mental Disorders

Denmark

01/08/2026

Phase II

An Open-Label Phase IIa Trial Exploring the Safety, Tolerability, and Efficacy of the T Cell Engager OM336 for Desensitization of Kidney Transplant Candidates

2025-523222-40-00End stage renal failure

DrugsDiphenhydramine·Paracetamol·Dexamethasone

Medical University Of Vienna

Pathological Conditions, Signs and Symptoms

Austria

31/07/2026

Phase II

A Multicenter, Open-Label, Long-Term, Safety and Tolerability Extension Study of PTI5803 as adjunctive therapy in patients ≥ 14 years of age with drug-resistant seizures associated to focal cortical dysplasia.

2026-525161-40-00Drug resistant focal epilepsy related to focal cortical dys…

DrugPTI5803

PannTheraPi

Nervous System Diseases

France

31/07/2026

Phase II

A Phase 2 Study of Alisertib in Combination with Paclitaxel in Patients with Small Cell Lung Cancer

2026-525382-47-00Small Cell Lung Cancer (SCLC)

Puma Biotechnology Inc.

Neoplasms

France, Poland, Spain

28/07/2026

Phase II

OBINUSS - Safety and efficacy of obinutuzumab in systemic sclerosis: a phase II, randomized, double-blinded versus placebo-controlled trial

2025-524003-68-00Patients with newly or active diffuse Systemic sclerosis at…

DrugObinutuzumab

Assistance Publique Hopitaux De Paris

Immune System Diseases

France

28/07/2026

Phase II

A Cancer Research UK Phase II trial of CY-101 given via intratumoural administration in locally advanced or metastatic adrenocortical carcinoma (CLARITY)

2025-522757-19-00LOCALLY ADVANCED OR METASTATIC ADRENOCORTICAL CARCINOMA

Cancer Research UK

Neoplasms

Spain, France, Germany, Norway

27/07/2026

Phase II

A Phase 2 Study Evaluating the Safety and Efficacy of Neoadjuvant Amivantamab in Combination with Lazertinib or Chemotherapy in Resectable EGFR-Mutated Non-Small Cell Lung Cancer

2025-524816-13-00Non-small Cell Lung Cancer

DrugsLazertinib·Amivantamab

Janssen Cilag International

Neoplasms

Spain

27/07/2026

Phase II

Evaluation of the effect of botulinum toxin on refractory upper limb rest tremor in parkinsonian patients, double-blind, placebo-controlled cross-over study : TOX PARK

2026-525862-23-00parkinson disease

DrugsDysport·NaCl

Centre Hospitalier Universitaire De Toulouse

Nervous System Diseases

France

24/07/2026

Phase II

DECREASE-IPC 2025-068 : De-Ecalating neoadjuvant Chemoimmunotherapy in early triple-negative BREASt cancer

2025-525040-18-00triple‑negative breast cancer

DrugsEndoxan·Paclitaxel·Pembrolizumab

Institut Paoli Calmettes

Neoplasms

France

24/07/2026

Phase II

functional imaging of digital osteoarthritis and rheumatoid arthritis using 99mTc-NTP15-5 in nuclear medicine : phase II clinical study

2025-523650-14-00Arthritis rheumatoid and finger osteoarthritis

Centre Jean Perrin

Not possible to specify

France

24/07/2026

Phase II

A randomised active-controlled trial to assess the safety and pharmacodynamics of two blinded doses of vortosiran and open-label apixaban in patients with non-valvular atrial fibrillation

2026-525417-31-00non-valvular atrial fibrillation

DrugsRBD4059·Apixaban

Ribocure Pharmaceuticals AB

Cardiovascular Diseases

Norway, Denmark, Poland, Sweden

24/07/2026

Phase II

Immune dynamics and biomarkers of anti-tumor response in BMS-986340 (anti-CCR8) and nivolumab (anti-PD-1) co-treatment of metastatic tumors

2025-524125-40-01Metastatic solid tumors, with the following specific indica…

DrugNivolumab

Humanitas Mirasole S.p.A., Fondazione Humanitas Per La Ricerca Ets

Neoplasms

Italy

23/07/2026

Phase II

A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of SIR9900 in Patients with VEXAS Syndrome (SIVEX)

2025-524918-28-00VEXAS Syndrome

Sironax USA Inc.

Immune System Diseases

Italy

23/07/2026

Phase II

IKF-099/D-FLOT-TNT Total Neoadjuvant Treatment with preoperative FLOT/Durvalumab plus postoperative Durvalumab for Resectable Gastroesophageal Adenocarcinoma

2026-525185-21-00Gastroesophageal Adenocarcinoma

Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Digestive System Diseases

Germany, Spain

23/07/2026

Phase II

Local and systemic immune modulation by Rilvegostomig (AZD2936) in the treatment of advanced gastric cancer (RILVE Project)

2026-525620-23-00advanced gastric cancer

DrugsRilvegostomig·Pembrolizumab

Vall D Hebron Institute Of Oncology

Neoplasms

Spain

22/07/2026

Phase II

A Phase 2, Multicenter, Randomized, Double-blind, Placebocontrolled Study, to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Intrathecally Administered Mivelsiran in Adult Participants with Early-Stage Down Syndrome-Associated Alzheimer’s Disease (DS-AD)

2025-523390-42-00Early-Stage Down Syndrome-Associated Alzheimer’s Disease (D…

DrugMivelsiran

Alnylam Pharmaceuticals Inc.

Nervous System Diseases

Italy, Netherlands, Spain, Germany, Ireland

22/07/2026

Phase II

Randomized Controlled Trial Assessing the Effectiveness and Safety of Fecal Microbiota Transfer for VRE Eradication in Immunocompromised Patients (EU CTR, Phase II) – VRE-ex

2026-525632-41-00Intestinal colonization with vancomycin-resistant enterococ…

Fraunhofer Institute For Translational Medicine And Pharmacology ITMP

Bacterial Infections and Mycoses

Germany

21/07/2026

Phase II

A Phase 2, open-label, randomized, dose optimization study evaluating the efficacy and safety of belantamab mafodotin administered in combination with cyclophosphamide, bortezomib, and dexamethasone in adult participants with newly diagnosed amyloid light chain amyloidosis (ALANIS)

2025-522803-60-00newly diagnosed amyloid light chain amyloidosis

DrugsEndoxan·Velcade·Bortezomib

Glaxosmithkline Research & Development Limited

Immune System Diseases

Italy, Greece, Spain

21/07/2026

Phase II

J2J-MC-JZLL - preEMBER: A Phase 2, Open-label Study Evaluating Imlunestrant in Premenopausal Women with Estrogen Receptor-Positive, HER2-Negative Breast Cancer.

2025-523258-15-00Breast Neoplasms

DrugsGoserelin·Tamoxifen

Eli Lilly & Co.

Neoplasms

Belgium, France, Italy, Germany, Ireland

21/07/2026

Phase II

DOXYCYCLINE PENETRATION INTO BONE AND JOINT.

2025-524744-36-00Patients requiring total hip arthroplasty for coxofemoral o…

DrugDoxycycline

Centre Hospitalier Universitaire De Caen Normandie

Bacterial Infections and Mycoses

France

20/07/2026

Phase II

Randomized Phase II study of multi-peptide vaccination and bispecific PSMAxCD3 antibody treatment in patients with biochemical relapse of prostate cancer

2025-522144-41-00biochemical relapse of prostate cancer

Universitaetsklinikum Tuebingen AöR

Male Urogenital Diseases

Germany

20/07/2026

Phase II

HOVON 180 CLL: Prospective phase II trial of pirtobrutinib treatment (24 cycles) with 12 cycles of epcoritamab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. ODYSSEUS study (Outcome-Driven trial for relapsed CLL/SLL combining BTK and bispecific antibodY to improve outcome)

2025-524842-89-00chronic lymphocytic leukemia (CLL) and small lymphocytic ly…

Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Hemic and Lymphatic Diseases

Netherlands

20/07/2026

Phase II

A PHASE II, SINGLE ARM, OPEN LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF CEVOSTAMAB IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED A PRIOR BCMA TARGETING CAR T-CELL THERAPY

2026-525736-42-00Multiple Myeloma (MM)

F. Hoffmann-La Roche AG

Neoplasms

Germany

20/07/2026

Phase II

A Phase IIb, randomised, double-blind, placebo-controlled, multicentre study to evaluate the efficacy and safety of concomitant use of eplontersen and ALXN2220 compared with eplontersen and placebo in adult participants with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).

2025-523908-75-00Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

AstraZeneca AB

Cardiovascular Diseases

Germany, Italy, Spain, France, Sweden

20/07/2026

Phase II

A Phase 2a, multi centric, open label clinical study to explore the safety and tolerability, the pharmacokinetics and pharmacodynamics profile and first signs of efficacy of PTI5803 administered as adjunctive therapy with a 3-dose escalation regimen in patients >= 14 years of age with drug-resistant seizures associated to focal cortical dysplasia, followed by an optional open-label extension study.

2026-525162-21-00Drug resistant seizures associated to Focal Cortical Dyspla…

DrugPTI5803

PannTheraPi

Nervous System Diseases

France

20/07/2026

Phase II

An open label multicenter phase II study to investigate the efficacy, safety and tolerability of the Obe-cel in patients with minimal residual disease (MRD) of Philadelphia negative (Ph neg) B-precursor acute lymphoblastic leukaemia (B-ALL) - GMALL-OBECEL

2025-524169-26-00Ph-negative CD19 positive B-precursor ALL patients in CR1 w…

DrugAUTO1

Goethe University Frankfurt

Hemic and Lymphatic Diseases

Germany

20/07/2026

Phase II

SETRAPED : A prospective, multicenter study evaluating the efficacy and tolerance of transmucosal midazolam for proportionate palliative sedation in children with refractory symptoms

2025-523840-11-00Children with refractory symptoms

DrugMidazolam

Centre Leon Berard

Pathological Conditions, Signs and Symptoms

France

17/07/2026

Phase II

An Open-Label Study to Assess the Hemodynamic Effect and the Safety of TX000045 After 16 Weeks of Treatment in Participants With Pulmonary Hypertension due to Interstitial Lung Disease

2026-525810-80-00Pulmonary hypertension secondary to interstitial lung disea…

Tectonic Operating Company Inc.

Cardiovascular Diseases

Poland, Romania, Spain

17/07/2026

Phase II

Tolerability and efficacy of treating locally advanced Resectable Oral Cancer with neoadjuvant INtratumoral anti-CTLA4 ImmunoTherapy combined with systemic anti-PD-1 (ROCinIT).

2025-523617-29-01Oral cavity squamous cell carcinoma

DrugsIpilimumab·Nivolumab

Amsterdam UMC Stichting

Neoplasms

Netherlands

17/07/2026

Phase II

PITALC. Pilot study on the effect of PITAC (Pressurized IntraThoracic Aerosol Chemotherapy) by videothoracoscopy in patients with malignant pleural effusion in the light of the results of a retrospective historical cohort treated with talc pleurodesis by videothoracoscopy

2025-523482-23-00neoplastic pleural effusion

Hospices Civils De Lyon

Neoplasms

France

16/07/2026

Phase II

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Confirm Efficacy and Safety of MH002 and to Assess the Effect of Dose in Patients With Mild-to-Moderate Ulcerative Colitis Insufficiently Controlled With 5-Aminosalicylic Acid

2025-524682-24-00Ulcerative Colitis

Microbial Resource Management Health

Digestive System Diseases

Czechia, Poland, Italy

16/07/2026

Phase II

Randomized, observer-blind, placebo-controlled, four Parallel Group, Clinical Trial for exploring the Efficacy and Tolerability of two different strengths ketotifen nasal spray (Ketotifen 0.025 mcg/ml and 0.050 mcg/ml) vs sodium cromoglicate nasal spray 2% in Patients with Rhinitis

2026-525419-16-00Rhinitis

Eudemus Pharmaceuticals Limited

Otorhinolaryngologic Diseases

Greece

16/07/2026

Phase II

Obinutuzumab for systemic lupus erythematosus pure membranous nephropathy: a phase II trial (OBLUMEN)

2024-519985-35-00systemic lupus erythematosus pure membranous nephropathy

DrugObinutuzumab

Assistance Publique Hopitaux De Paris

Pathological Conditions, Signs and Symptoms

France

15/07/2026

Phase II

COLOVERT – Conversion therapy in colorectal cancer with peritoneal metastases not amenable to upfront cytoreductive surgery and HIPEC: a phase II “pick-the-winner” open-label randomized trial

2026-526122-41-00Colorectal cancer with peritoneal metastases

DrugsMitomycin C·Doxorubicin·Irinotecan·Oxaliplatin

Uppsala University Hospital

Not possible to specify

Sweden

15/07/2026

Phase II

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-755 in Acute Ischemic Stroke

2025-522734-31-00Acute Ischemic Stroke

Takeda Development Center Americas Inc.

Nervous System Diseases

Greece, Belgium, France, Germany

14/07/2026

Phase II

A Phase II, Open-Label, Single-Arm, Multicentre Study of Immunotherapy and non-invasive response evaluation in cutaneous squamous cell carcinoma as an organ preservation strategy: a proof of concept clinical study and translational correlates - INCEPT

2025-523633-25-00cutaneous squamous cell carcinoma

DrugCemiplimab

Fondazione GONO Plus

Neoplasms

Italy

14/07/2026

Phase II

A Phase 2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Surovatamig in Adults with Antibody-mediated Kidney Disease

2025-524139-38-00Antibody-mediated Kidney Disease

DrugSurovatamig

AstraZeneca AB

Immune System Diseases

France, Germany, Italy, Belgium, Poland, Spain

13/07/2026

Phase II

Phase II, Multicenter, Randomized Study to Evaluate Safety and Efficacy of MRD-guided Therapy with Reduced versus Standard Dose of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (REBEL)

2025-525096-83-00Relapsed/refractory Multiple myeloma

DrugPomalidomide

Polish Myeloma Consortium

Hemic and Lymphatic Diseases

Poland

13/07/2026

Phase II

Inducing durable immunological control of HIV-1 through administration of long-acting broadly neutralizing antibodies and low-dose anti-PD-1 – a randomized, double-blinded, placebo-controlled trial (the IDUNN trial)

2025-523725-17-00HIV-1 disease

DrugsTeropavimab·Zinlirvimab·Nivolumab

Region Midtjylland

Immune System Diseases

Sweden, Norway, Denmark, Iceland

13/07/2026

Phase II

A Phase 1b-2, Multicenter, Trial to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of REC-4881 in Patients with Familial Adenomatous Polyposis (FAP)

2026-525282-50-00Familial Adenomatous Polyposis

Recursion Pharmaceuticals Inc.

Neoplasms

Netherlands, Germany, Spain

13/07/2026

Phase II

SUNCET: Low sodium oxybate Use for Nocturnal Cluster headache: safety, Efficacy and Tolerability of XYWAV - a Phase 2 Randomized, Double-Blind, Placebo-Controlled, bi-center Study

2025-523293-17-00Cluster headache

Leids Universitair Medisch Centrum (LUMC)

Nervous System Diseases

Netherlands

13/07/2026

Phase II

Achieving viral CLEARance in immunocompromised participants with long-term persistence of SARS-CoV-2 - an open-label randomized trial (CLEAR)

2025-524442-10-00Long-term persistence of SARS-CoV-2

DrugsPaxlovid·Remdesivir

Goethe University Frankfurt

Virus Diseases

Germany, Spain

13/07/2026

Phase II

Prospective trial of [18F]AlF-FAPI-74 for PET imaging of fibroblast activation protein in patients with endometriosis

2026-525272-25-00endometriosis

UZ Leuven

Female Urogenital Diseases and Pregnancy Complications

Belgium

10/07/2026

Phase II

A Phase 2, Open-Label, Single-Arm Study of Lirafugratinib in Patients With Previously Treated, Unresectable, Locally Advanced or Metastatic Solid Tumors (Excluding Cholangiocarcinoma) With FGFR2 Fusion or Rearrangement

2025-523923-22-00Previously Treated, Unresectable, Locally Advanced or Metas…

Elevar Therapeutics Inc.

Neoplasms

France, Spain

09/07/2026

Phase II

Giving Upfront Anti-p40 to Reduce toxicity from Dual Immune Checkpoint Inhibition in MESOthelioma

2026-526036-38-00Pleural mesothelioma

DrugUstekinumab

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Neoplasms

Netherlands

09/07/2026

Phase II

Master Protocol Full Title- A Master Protocol for an Exploratory, Phase 2a, Proof-of-Concept Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis. ISA 2 to Master Protocol ARGX-999-2-MG-2000 – an Exploratory, Phase 2a, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis

2025-522939-33-00AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthe…

DrugEmpasiprubart

Argenx

Immune System Diseases

Greece, Italy, Germany, Belgium, Netherlands, Spain, Poland

08/07/2026

Phase II

Open-label, single-center, single-arm phase 2 futility trial evaluating the oral indapamide for reducing progression of disability in people with primary and secondary progressive multiple sclerosis (MS)

2026-525260-18-00Multiple Sclerosis

DrugIndapamide

Amsterdam UMC Stichting

Nervous System Diseases

Netherlands

08/07/2026

Phase II

A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of E2086 in Adults with Narcolepsy

2025-523503-30-00Narcolepsy

Eisai Limited

Nervous System Diseases

Belgium, Italy, Spain, Germany

08/07/2026

Phase II

HMBeacon: A Phase 2, Randomized, Double-blind Study of the Safety, Tolerability, Efficacy, and Pharmacodynamics of Multiple Dose ALN-6400 in Female Patients with Von Willebrand Disease (VWD) and Heavy Menstrual Bleeding (HMB)

2025-524967-19-00Von Willebrand Disease (VWD) and Heavy Menstrual Bleeding (…

Alnylam Pharmaceuticals Inc.

Cardiovascular Diseases

Netherlands, Sweden, Germany

08/07/2026

Phase II

A Phase 2 Open-Label, Multi-Center Study of BMS-986504 as Monotherapy and in Combination with Other Agents in Participants with Advanced and/or Metastatic Solid Tumors with Homozygous MTAP Deletion

2025-524285-18-00Advanced and/or Metastatic Solid Tumors with Homozygous MTA…

Bristol-Myers Squibb Services Unlimited Company

Neoplasms

Belgium, Ireland, Germany, Norway, Italy, France, Spain

07/07/2026

Phase II

A Phase 2 Randomized, Double-blind, Placebo-Controlled Study to Assess the Safety and Efficacy of MTX-474 in the Treatment of Participants with Diffuse Cutaneous Systemic Sclerosis (dcSSc)

2025-523288-39-00Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Mediar Therapeutics Inc.

Immune System Diseases

Netherlands, Romania, Poland, France, Italy, Spain

06/07/2026

Phase II

Immunogenicity and safety of two respiratory syncytial virus vaccine strategies in lung and allogeneic haematopoietic stem cell transplant recipients: A phase 2 trial RSVaxID

2025-524374-42-00allogeneic haematopoietic stem cell transplant recipient, l…

DrugVaxzevria

Hospices Civils De Lyon

Surgical Procedures, Operative

France

06/07/2026

Phase II

Shared decision-making in uncomplicated appendicitis: a pragmatic randomized trial comparing patient-driven choice (antibiotics only or appendectomy) with systematic appendectomy (FRENCH 47 — ALACARTE trial)

2025-520783-17-01Adult patients diagnosed with uncomplicated acute appendici…

Assistance Publique Hopitaux De Paris

Therapeutics

France

06/07/2026

Phase II

Feasibility of fluorescence imaging with bevacizumab-800CW during bronchoscopy in patients with a pulmonary lesion considered to be malignant - DFLECT I

2024-510793-24-00suspected malignant pulmonary disease (lung lesions and/or …

DrugBevacizumab

Universitair Medisch Centrum Groningen

Neoplasms

Netherlands

06/07/2026

Phase II

iSTOP-CP: intranasal Stem Cells to treat Perinatal brain injury to combat Cerebral Palsy

2025-521506-17-01Hypoxic-ischemic brain injury (HIBI) because of Perinatal A…

Universitair Medisch Centrum Utrecht

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Netherlands

06/07/2026

Phase II

The Acute and Long-term Impact of Support in Psilocybin Therapy for Depression: The Psilocybin Setting Trial (PSISET)

2025-522961-31-01Depression

DrugPsilocybin

Kobenhavns Universitet, Koebenhavns Universitet

Mental Disorders

Denmark

03/07/2026

Phase II

Individualized Intrathecal Chemotherapy Based on Measurement of Brain Fluid Clearance in Pediatric Patients

2025-522453-20-00Acute lymphoblastic leukemia and lymphoma

DrugGadobutrol

Oslo University Hospital HF

Neoplasms

Norway

03/07/2026

Phase II

A Randomized, Delayed-Treatment Controlled, Phase 2 Pilot Study of Manualized MDMA-Assisted Therapy for Young Adults with Chronic Treatment-Resistant Major Depressive Disorder

2024-520319-42-01Major Depressive Disorder

DrugMidomafetamine HCl

Ostfold Hospital Trust

Psychological Phenomena

Norway

03/07/2026

Phase II

A multicenter open-label phase II study of Cemiplimab plus chemotherapy, selected on the basis of baseline cytidine deaminase activity, in advanced squamous non-small cell lung cancer - CECYDE trial - GOIRC-04-2024

2024-517799-40-00Advanced squamous non-small cell lung cancer

DrugCemiplimab

G.O.I.R.C. Gruppo Oncologico Italiano Di Ricerca Clinica

Neoplasms

Italy

03/07/2026

Phase II

Interleukin-1 inhibition to improve the response of myeloproliferative neoplasms resistant to cytoreductive treatment

2025-523921-17-00myeloproliferative neoplasms

DrugAnakinra

Centre Hospitalier Regional Et Universitaire De Brest

Hemic and Lymphatic Diseases

France

02/07/2026

Phase II

18F-fluoro-ethyl-tyrosine (18FET) PET for difficult clinical situations in functional pituitary adenoma. A prospective, single arm, single center study. (FET-PIT)

2025-523829-17-00Patients (male or female) ≥18 years old with Suspected func…

Centre Hospitalier Universitaire De Lille

Diagnosis

France

02/07/2026

Phase II

IFCT-2501 IDEATION ctDNA-guIDEd consolidATION immunotherapy after chemoradiotherapy in patients with stage III non-small cell lung cancer

2025-522801-39-00Stage III Non Small Cell Lung Cancer

DrugDurvalumab

Intergroupe Francophone De Cancerologie Thoracique

Neoplasms

France

02/07/2026

Phase II

High-dose Insulin Euglycemic Therapy in Non-Toxic Acute Cardiogenic Shock.

2025-523858-13-01Non-toxic acute cardiogenic shock

DrugHumalog

Oslo Universitetssykehus HF

Cardiovascular Diseases

Norway

01/07/2026

Phase II

A Phase II, Randomized, Double-blind, 3-Period Cross-over, Dose‑ranging Study to Assess the Efficacy and Safety of Glycopyrronium (GP) versus Placebo in Participants of 4 to Less than 12 Years of Age with Asthma Receiving Background Budesonide and Formoterol Fumarate (BFF) (FAROS)

2025-524914-26-00Asthma

AstraZeneca AB

Respiratory Tract Diseases

Czechia, Poland, Hungary

01/07/2026

Phase II

A phase IIa, single-arm, single-center, open label, proof-of-concept trial evaluating increased frequency dosing of VCN-01 (zabilugene almadenorepvec) in combination with nab-Paclitaxel/Gemcitabine (GnP) in Patients with Newly-Diagnosed Metastatic Pancreatic Cancer (VIRAGE2)

2026-525566-21-00metastatic pancreatic adecarcinoma

Theriva Biologics S.L.

Neoplasms

Spain

30/06/2026

Phase II

C6461014 - A Phase 2 Interventional Study of PF-08634404 in Combination with Chemotherapy in Participants with Previously Untreated Transformed Small Cell Lung Cancer

2025-524686-24-00Small Cell Lung Cancer

DrugsPF-08634404·Etoposide·Carboplatin

Pfizer Inc.

Neoplasms

France, Italy, Spain

29/06/2026

Phase II

Randomised open-label pilot Study on Thiamine supplementation to REduce braiN injury associated with chronic Alcohol use in outpatients with alcohol use disorder : STRENA

2025-524148-36-00Alcoholism

Institut National De La Sante Et De La Recherche Medicale

Mental Disorders

France

29/06/2026

Phase II

A Master Protocol of a Phase II, Open-label, Multicenter, Global Platform Study to Evaluate the Safety and Efficacy of Immunotherapy With or Without Other Anticancer Drugs in Participants with Unresectable Stage III Non-small Cell Lung Cancer Planning to Undergo Concurrent Chemoradiotherapy (AQUARIUS)

2025-523599-21-00Non-small Cell Lung Cancer

DrugsMycophenolate Mofetil·Infliximab·Rilvegostomig·Pemetrexed

AstraZeneca AB

Neoplasms

Spain, Germany

29/06/2026

Phase II

“In vivo” biological standardization of the allergenic extracts Dermatophagoides pteronyssinus (DPT) and Dermatophagoides farinae (DF) in patients sensitized to them.

2026-525628-13-00IgE-mediated respiratory allergic disease due to the allerg…

Probelte Pharma S.L.

Disorders of Environmental Origin

Spain

26/06/2026

Phase II

An open-label multiple dose safety, tolerability and exploratory efficacy clinical trial of PST-611 in patients with geographic atrophy secondary to age-related macular degeneration

2025-525008-12-00Geographic atrophy secondary to age-related macular degener…

PulseSight Therapeutics

Eye Diseases

France

25/06/2026

Phase II

A Randomized, Double-blinded, Placebo-controlled, Parallel Group, Phase 2a Study to Assess the Activity, Safety, and Tolerability of SAR445399 in Adult Participants with Non-Cystic Fibrosis Bronchiectasis (NCFB).

2025-523403-29-00Non-cystic fibrosis bronchiectasis

Sanofi-Aventis Recherche & Developpement

Respiratory Tract Diseases

Poland, Spain, France, Netherlands, Germany

23/06/2026

Phase II

An Open-Label Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents with Relapsing-Remitting Multiple Sclerosis

2025-524164-37-00Relapsing-Remitting Multiple Sclerosis (RRMS)

DrugOcrelizumab

F. Hoffmann-La Roche AG

Nervous System Diseases

Poland, Germany, France

23/06/2026

Phase II

A Phase IIb, Non-Profit, Open-label Trial for the Intrathecal Administration of AAV9/AP4M1 for Hereditary Spastic Paraplegia Type 50 (SPG50).

2025-524481-15-00Heriditary spastic paraplegia (SPG50)

Rigshospitalet, Elpida Therapeutics SPC

Nervous System Diseases

Denmark

23/06/2026

Phase II

Efficacy of asciminib in chronic phase CML patients with T315l mutations

2025-523491-23-00Chronic Myeloid Leukemia

DrugAsciminib

Friedrich-Schiller-Universitaet Jena

Neoplasms

Germany

23/06/2026

Phase II

An Open-label, Single-Arm, Phase 2 Study to Evaluate Enfortumab Vedotin plus Pembrolizumab for Bladder Preservation in Participants with Muscle-invasive Bladder Cancer (EV-209).

2025-524488-18-00Muscle-invasive Bladder Cancer

Astellas Pharma Global Development Inc.

Neoplasms

Germany, France, Poland, Italy, Spain

22/06/2026

Phase II

A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-8690 in Adult Participants with Moderately to Severely Active Ulcerative Colitis

2025-523479-49-00Colitis ulcerative

Merck Sharp & Dohme LLC

Digestive System Diseases

Italy, Greece, Netherlands, Poland, Germany, France

22/06/2026

Phase II

Open-Label Extension Study to Provide Continued Access to Avutometinib Alone or in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

2025-524713-88-00Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

Verastem Inc.

Neoplasms

France

22/06/2026

Phase II

Psilocybin-Assisted Psychotherapy for Posttraumatic Stress Disorder in Military Veterans: A Pilot Feasibility Study

2025-521488-11-00Posttraumatic stress disorder

DrugPsilocybin

ARQ National Psychotrauma Centrum

Mental Disorders

Netherlands

22/06/2026

Phase II

Supplementary Oxygen Therapy after Limb Debridement and Reconstruction Surgery in Infected Extremity Fractures (SOLDIER): a pilot, non-blinded, randomized controlled trial

2026-525871-24-00Fracture-Related Infection

Amsterdam UMC Stichting

Musculoskeletal Diseases

Netherlands

22/06/2026

Phase II

A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 for the Treatment of Narcolepsy with Cataplexy (Narcolepsy Type 1)

2025-522587-33-00Narcolepsy with Cataplexy (NT1)

Takeda Development Center Americas Inc.

Nervous System Diseases

Spain, Italy, France

22/06/2026

Phase II

Pain Relief at Screening for Retinopathy of Prematurity - The PROPER study

2023-507975-23-01Retinopathy of prematurity

DrugDexmedetomidine

St. Olavs Hospital HF

Eye Diseases

Norway

22/06/2026

Phase II

A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety and Efficacy of AGA2115 in Adults with Type I, III, or IV Osteogenesis Imperfecta (OI)

2025-522951-24-00Osteogenesis Imperfecta

DrugAGA2115

Angitia Inc. Ltd.

Musculoskeletal Diseases

Netherlands, France, Denmark

22/06/2026

Phase II

A Phase 2, Randomized, Double-blind, Placebo-controlled Crossover Study Evaluating the Efficacy and Safety of LTG-321 in Patients with Osteoarthritis of the Knee

2026-525966-22-00Osteoarthritis of the knee

Latigo Biotherapeutics Inc.

Musculoskeletal Diseases

Denmark

22/06/2026

Phase II

Epcoritamab in Relapsed/Refractory Marginalzone Lymphoma - A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY (EPOS-1)

2025-524879-23-00Marginal Zone Lymphoma

Universitaetsklinikum Ulm AöR

Hemic and Lymphatic Diseases

Germany

19/06/2026

Phase II

A randomized, double-blind, placebo-controlled, 104-week proof-of-concept study to evaluate the efficacy of intravenous prasinezumab in participants with Parkinson's disease carrying a severe mutation in the GBA gene (prevent cognitive decline in GBA-associated PD)

2024-513496-40-00PARKINSON’S DISEASE

DrugPrasinezumab

Universitaetsklinikum Tuebingen AöR

Nervous System Diseases

Spain, Germany, Italy, Sweden, France, Luxembourg

18/06/2026

Phase II

Preventive effect of 5% lidocaine patch on the development of neuropathic pain following an osteoporotic vertebral fracture: A proof-of-concept, controlled, randomized trial

2025-524889-25-00Osteoporotic Fracture

University Hospital Of Clermont-Ferrand

Musculoskeletal Diseases

France

17/06/2026

Phase II

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Nemolizumab in Adult Patients with Systemic Sclerosis, including a 52-Week Main Treatment Period and a 156-Week Extension Treatment Period

2025-522294-11-00Systemic sclerosis

Galderma S.A.

Skin and Connective Tissue Diseases

Poland, Italy, Bulgaria, France, Greece, Spain, Croatia

17/06/2026

Phase II

RADICAL-IO: thRee cycles of immunotherApy without raDical therapy In mediCALly InOperable stage I non-small cell lung cancer

2025-524305-32-00Stage I non-small cell lung cancer

DrugCemiplimab

Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Respiratory Tract Diseases

Netherlands

16/06/2026

Phase II

A Phase 2, Open-Label Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE)

2025-525124-10-00Duchenne Muscular Dystrophy

DrugsENTR-601-44·ENTR-601-45

Entrada Therapeutics Inc.

Musculoskeletal Diseases

Belgium, Italy, Netherlands, Spain

16/06/2026

Phase II

A Study to Evaluate the Long-term Safety and Efficacy of Long-acting Antibodies as Single Agents and in Combinations in Participants with Inflammatory Bowel Disease

2025-524640-35-00Ulcerative colitis (Inflammatory Bowel Disease)

DrugsSPYPBO-101·SPY001·SPY002·SPY003

Spyre Therapeutics Inc.

Digestive System Diseases

Croatia, Poland, Austria, Czechia, Italy, Slovakia, Bulgaria, Greece, Belgium, Spain, Hungary, Germany, Lithuania, France, Romania

16/06/2026

Phase II

A single arm single center exploratory observational phase II study, aimed to detect long term changes in volume of port-wine macrocheilia and color of port-wine stain in patients undergoing surgery and laser therapy during sirolimus treatment. Quality of life and efficacy and safety of sirolimus will be assessed.

2024-511937-37-01Vascular malfomation

DrugSirolimus

Oslo University Hospital HF

Hemic and Lymphatic Diseases

Norway

15/06/2026

Phase II

A Phase II, Open-label, Multicenter Study Testing Teclistamab in Combination with Pomalidomide Administered in Alternative Fashion in Participants with RRMM, who Received 1 - 3 Prior Lines of Therapy, Including Lenalidomide and Anti-CD38 Therapy

2025-522114-23-00Multiple myeloma (RRMM)

Odense University Hospital

Neoplasms

Finland, Denmark, Estonia, Norway

15/06/2026

Phase II

Exploratory study evaluating the relevance of [68Ga]Ga-FAPI-46 for staging and identifying progressing patients with transthyretin cardiac amyloidosis

2025-523616-36-00Transthyretin cardiac amyloidosis

Centre Hospitalier Universitaire De Nantes

Diagnosis

France

13/06/2026

Phase II

A PHASE 2 STUDY OF STRIDE (durvalumab + tremelimumab) With Lenvatinib Versus STRIDE Alone in Patients With Unresectable Hepatocellular Carcinoma (SLIDE-HCC) - HE.2

2025-521608-23-00patients with unrestectable hepatocellular carcinoma (SLIDE…

DrugsTremelimumab·Durvalumab·Lenvatinib

IRCCS Istituto Nazionale Tumori Fondazione Pascale

Neoplasms

Italy

12/06/2026

Phase II

J6Z-MC-IIBD - A Master Protocol for Phase 2, Randomized, Controlled Studies of Multiple Interventions for the Treatment of Adults With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease J6Z-MC-CD01 - A Phase 2, Multicenter, Randomized, Open-Label, Active-Controlled Study to Investigate LY4395089/Mirikizumab Co-administration Compared with Mirikizumab in Adults with Moderately to Severely Active Crohn’s Disease

2025-524112-11-00J6Z-MC-IIBD - Colitis, Ulcerative Crohn Disease J6Z-MC-CD…

DrugMirikizumab

Eli Lilly & Co.

Digestive System Diseases

Italy, Germany, Hungary, Poland, Belgium

11/06/2026

Phase II

A Phase 2, Open-Label, Multicenter, Randomized Study to Evaluate Denikitug as Monotherapy or in Combination With Nivolumab or Chemotherapy in Participants With HER2-Negative, Unresectable, Recurrent, and/or Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas

2025-524095-27-00HER2-negative, unresectable, recurrent, and/or metastatic g…

Gilead Sciences Inc.

Neoplasms

Spain, France

11/06/2026

Phase II

J6E-MC-KWAM: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Development Program to Evaluate the Efficacy and Safety of LY4268989 (MORF-057) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis (EMERALD-3)

2025-524404-29-00Ulcerative Colitis, Active Severe, Ulcerative Colitis, Acti…

Eli Lilly & Co.

Digestive System Diseases

Latvia, Portugal, Greece, France, Czechia, Italy, Poland, Slovakia, Hungary, Croatia, Lithuania

10/06/2026

Phase II

A multicenter, randomized, double-blind, placebo-controlled, dose-ranging Phase IIb study to assess the efficacy and safety of GIA632 in adult participants with non-segmental vitiligo followed by an extension period

2025-522301-37-00Nonsegmental vitiligo

Novartis Pharma AG

Skin and Connective Tissue Diseases

Germany, Spain, Netherlands, France, Italy

08/06/2026

Phase II

J5D-MC-FPAC: A Phase 2a, Randomized, Multicenter, Double-Blind, Placebo-Controlled Proof of Concept Study to Investigate Efficacy and Safety of LY4005130 in Adult Participants With Severe Alopecia Areata

2025-524727-41-00Alopecia Areata

Eli Lilly & Co.

Immune System Diseases

Poland, Netherlands

08/06/2026

Phase II

A Phase 2, Open Label, Multicenter, Randomized Study, to Evaluate the Efficacy and Safety of Denikitug Monotherapy and Denikitug-based Combinations in Participants With Advanced Microsatellite Stable (MSS) Colorectal Cancer (CRC).

2025-523984-39-00Advanced Microsatellite Stable (MSS) Colorectal Cancer (CRC)

Gilead Sciences Inc.

Neoplasms

Spain, Italy, France

08/06/2026

Phase II

REpurposed drug evaluation for DEceleration of immunE aging & Mitigation of chronic inflammation (REDEEM)

2026-526084-38-00Immune Aging, Chronic inflammation

Radboud universitair medisch centrum Stichting

Immune System Diseases

Netherlands

08/06/2026

Phase II

Radium223 dichloride (223RaCl) in the treatment of symptomatic bone metastases from breast cancer.

2025-524208-31-00Symptomatic bone metastases from breast cancer

DrugsExemestane·Anastrozole·Letrozole

Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone

Neoplasms

Italy

08/06/2026

Phase II

C4531031 - AN INTERVENTIONAL PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, THIRD PARTY-UNBLINDED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF PF-07275315 IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

2024-518587-12-00MODERATE-TO-SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (C…

Pfizer Inc.

Respiratory Tract Diseases

Spain, Germany, Poland, Czechia, Greece, Italy, Bulgaria, France, Hungary

08/06/2026

Phase II

An open-label, non-randomized, single center, single dose, exploratory phase II trial of FG001 (an imaging agent) in combination with transoral robotic surgery for oropharyngeal squamous cell carcinoma and neck dissection surgery for oral squamous cell carcinoma with regional lymph node metastases

2025-522845-23-00Oral Squamous Cell Carcinoma with neck metastases, Orophary…

Rigshospitalet

Neoplasms

Denmark

08/06/2026

Phase II

Phase II, Single-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial To Evaluate The Safety And Efficacy Of Dasatinib To Reduce HIV-1 Reservoir, Chronic Inflammation, And Immune Senescence In People With HIV On Long-Term Antiretroviral Treatment.

2025-524363-20-01HIV-1 infection

DrugDasatinib

Instituto De Salud Carlos III

Virus Diseases

Spain

08/06/2026

Phase II

Phase II, Placebo-controlled trial of Cannabidiol for the treatment of alcohol dependence (PLACONCANALDE)

2023-504439-42-03alcohol dependence

DrugCannabidiol

Hospital Universitario 12 De Octubre

Behavioral Disciplines and Activities

Spain

08/06/2026

Phase II

Phase IIb Multicenter Randomized Controlled Trial Evaluating the Efficacy of Sivelestat in Patients with Septic Coagulopathy

2025-523397-16-00Septic Coagulopathy

Les Hopitaux Universitaires De Strasbourg

Investigative Techniques

France

05/06/2026

Phase II

Long-term outcomes and safety of repeated rituximab treatment in psychotic disorders – RITS-LONG

2026-525324-26-00Schizophrenia spectrum disorder (SSD)

DrugRituximab

Region Oerebro Laen

Mental Disorders

Sweden

05/06/2026

Phase II

Diagnostic Efficacy of 18F-FAPI-74 PET/CT in Patients with Gastric Cancer

2026-526494-42-00Gastric cancer

Varsinais-Suomen hyvinvointialue

Neoplasms

Finland

05/06/2026

Phase II

A Phase 2a Study of SUN-627 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Impact on Measures of Neuroinflammation in the Central Nervous System in Participants With Non-Active Progressive Multiple Sclerosis (SPMS/PPMS)

2026-525817-29-00Multiple Sclerosis; Primary Progressive Multiple Sclerosis;…

Sundance Biosciences Inc.

Nervous System Diseases

Finland

05/06/2026

Phase II

Cosmos Trial: Cerebroprotection Of AST-004 in Mild Complicated Traumatic Brain Injuries

2026-525554-11-00Traumatic brain injury

Astrocyte Pharmaceuticals Inc.

Nervous System Diseases

Netherlands

04/06/2026

Phase II

Prevention of radiation-induced salivary gland damage by botulinum toxin application in patients with head and neck cancers

2025-524720-22-00patients with head and neck squamous cell carcinoma (HNSCC)

DrugBotulinum toxin type A

Fakultni Nemocnice Kralovske Vinohrady

Otorhinolaryngologic Diseases

Czechia

02/06/2026

Phase II

A randomized, Phase 2a, double-blinded, biomarker-driven, placebo-controlled study to assess safety, CNS penetration, and target engagement of Mirivadelgat in Parkinson’s disease – SLEIPNIR-2, a sub-protocol in the SLEIPNIR platform trial

2025-523570-17-00Parkinson's Disease

Helse Bergen HF

Nervous System Diseases

Norway

02/06/2026

Phase II

Safety and efficacy of treatment combination with ponatinib and asciminib in chronic myeloid leukemia patients resistant to ponatinib and/or asciminib

2025-521126-15-00Chronic Myeloid Leukemia

Grupo Espanol De Leucemia Mieloide Cronica (GELMC)

Neoplasms

Spain

01/06/2026

Phase II

Sublingual Birch Immunotherapy for Pollen-associated Food Allergy

2025-523653-34-00Birch pollen Allergy, Pollen-associated Food Allergy

DrugMannitol

Klinikum der Technischen Universitaet Muenchen (TUM Klinikum)

Immune System Diseases

Germany

29/05/2026

Phase II

A PRECISION MEDICINE RANDOMIZED TRIAL FOR PATIENTS WITH RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON A FUNCTIONAL APPROACH. ALL-TARGET TRIAL

2024-516570-30-00Relapsed/refractory T-cell Acute Lymphoblastic Leukemia

DrugsAsparaginase Erwinia chrysanthemi·Tofacitinib·Everolimus·Azacitidine

Centre Hospitalier De Versailles

Hemic and Lymphatic Diseases

Germany, France, Czechia, Netherlands, Spain

29/05/2026

Phase II

Leveraging the neural mechanisms of social reward for drug relapse prevention

2023-504518-31-01substance use disorder

DrugOxytocin

Fondazione Santa Lucia IRCCS

Mental Disorders

Italy

29/05/2026

Phase II

Intravenous iron in the management of drug-resistant restless legs syndrome: a randomized controlled delayed-start trial. IRON-RLS

2026-525613-31-00Restless legs syndrome

DrugFerric Carboxymaltose

Centre Hospitalier Universitaire De Montpellier

Nervous System Diseases

France

29/05/2026

Phase II

J5D-MC-FPAD: A Phase 2a, Randomized, 24-Week, Multicenter, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Investigate Efficacy and Safety of LY4005130 in Adult Participants with Non-Segmental Vitiligo

2025-524726-18-00Vitiligo, Non-Segmental Vitiligo (NSV)

Eli Lilly & Co.

Immune System Diseases

Poland, Belgium

29/05/2026

Phase II

Pilot study comparing the efficacy of intra-articular glenohumeral injection combined with suprascapular nerve block versus intra-articular glenohumeral corticosteroid injection in adhesive capsulitis.

2026-525317-31-00Retractile Capsulitis

Centre Hospitalier Universitaire De Nantes

Musculoskeletal Diseases

France

29/05/2026

Phase II

A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX‑828/Deutivacaftor With and Without Tezacaftor in Subjects Aged 18 Years and Older With Cystic Fibrosis

2025-523400-72-00Cystic fibrosis

Vertex Pharmaceuticals Inc.

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Spain, Sweden, Germany, Italy, Belgium, Czechia, Ireland, Portugal, Netherlands, France, Denmark

29/05/2026

Phase II

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a Long-term Extension of Povetacicept in Adults with Generalized Myasthenia Gravis

2025-523950-15-01Generalized Myasthenia Gravis

Vertex Pharmaceuticals Inc.

Nervous System Diseases

Poland

29/05/2026

Phase II

Phase II Clinical Trial of KORTUC (KRC-01) Combined with Radiotherapy for Locally Advanced Rectal Cancer: Towards a New Organ Preservation Approach (K-BOOST)

2025-524378-40-00Locally advanced high‑risk stage III rectal adenocarcinoma …

DrugKortuc

Institut Gustave Roussy

Neoplasms

France

28/05/2026

Phase II

A Phase 2A/B, Multi-center, Open-Label Study Evaluating the Efficacy and Safety of Dabogratinib (TYRA-300) in Participants with Low Grade Upper Tract Urothelial Carcinoma (SURF303)

2025-523539-20-00Low Grade Upper Tract Urothelial Carcinoma

Tyra Biosciences Inc.

Neoplasms

Bulgaria, France, Spain

28/05/2026

Phase II

Dosing EvaLuation of Tenofovir Alafenamide on Epstein-Barr Virus (The DELTA-EBV study)

2025-522781-77-01Epstein-Barr virus infection

Helse Bergen HF

Virus Diseases

Norway

28/05/2026

Phase II

Efficacy of an anti-TSLP monoclonal antibody in the management of chronic bronchial disease induced by bronchiolitis obliterans syndrome in allogeneic hematopoietic stem cells transplantation recipients.

2024-516796-33-00The medical condition studied in IMMUNO-BOS is Bronchioliti…

Hospital Foch

Respiratory Tract Diseases

France

27/05/2026

Phase II

An Extension Study to Evaluate the Long-Term Safety and Efficacy of Afimkibart (RO7790121) in Patients with Rheumatoid Arthritis who Participated in Previous Afimkibart Clinical Trials

2025-523579-47-00moderate to severe rheumatoid arthritis (RA)

DrugAfimkibart

F. Hoffmann-La Roche AG

Immune System Phenomena

Italy, Spain, Germany, France, Denmark, Poland, Belgium

27/05/2026

Phase II

An Open-Label Study to Assess the Long-Term Safety and Tolerability of ML-007C-MA in Adult Participants with Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis

2025-521757-16-00Hallucinations and Delusions Associated with Alzheimer’s Di…

Maplight Therapeutics Inc.

Mental Disorders

Italy, Poland, Czechia, Portugal, Bulgaria, France, Slovakia, Romania, Hungary

27/05/2026

Phase II

POMREP - Efficacy and safety of zoledronate versus placebo on pain at week 12 in pediatric patients with chronic recurrent multifocal osteomyelitis resistant to non-steroidal anti-inflammatory drug

2023-506420-93-00Chronic recurrent multifocal osteomyelitis (CRMO)

DrugZoledronic Acid

Assistance Publique Hopitaux De Paris

Musculoskeletal Diseases

France

26/05/2026

Phase II

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma (r/r MM)

2025-524181-26-00relapsed/refractory multiple myeloma

C4 Therapeutics Inc.

Hemic and Lymphatic Diseases

Italy, France, Spain, Poland

25/05/2026

Phase II

UNLOCK - EPIBREAST, a phase II study of prifetrastat (PF-07248144), a KAT6 inhibitor, plus fulvestrant for advanced HR+/HER2- breast cancer with biomarkers analysis

2025-521982-29-00Adult patients with advanced hormone receptor positive (HR+…

DrugsPrifetrastat·Fulvestrant

Unicancer

Neoplasms

France

22/05/2026

Phase II

Safety and efficacy of T10430 eye drops in controlling paediatric myopia progression

2025-521563-13-01Paediatric myopia

Laboratoires Thea

Eye Diseases

Ireland, Austria

22/05/2026

Phase II

A phase 2 trial of BMS-986365 in mCSPC patients with suboptimal PSA-response after 7 months of Androgen Deprivation Therapy (ADT) plus Androgen Receptor Pathway Inhibition (ARPI).

2025-523672-23-00Metastatic Castrate Sensitive Prostate Cancer - mCSPC

UroTrials GmbH, AIO-Studien gGmbH

Male Urogenital Diseases

Germany

22/05/2026

Phase II

A Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Participants with Stage 4 Non-Small Cell Lung Cancer (TeLuRide-008).

2025-525013-23-00Stage 4 (IV) Non-Small Cell Lung Cancer (NSCLC)

DrugPembrolizumab

Eikon Therapeutics Inc.

Neoplasms

Germany, Spain, Netherlands, Romania, Greece, Italy, Austria, Belgium, Bulgaria, France, Hungary, Poland

21/05/2026

Phase II

An open-label, single-arm extension study to evaluate the long-term safety, tolerability, and efficacy of KL1333 (napazimone) in patients with primary mitochondrial disease

2025-524367-20-00Adult patients with primary mitochondrial disease

Pharming Technologies B.V.

Metabolism

Belgium, Germany, Czechia, Spain, Denmark, Italy, France, Netherlands

21/05/2026

Phase II

An Open-Label, Rollover Study for Participants With Thyroid Eye Disease Previously Enrolled in Amgen-Sponsored AMG 732 Studies and are Primary Proptosis Non-responders or who Relapsed During the Safety Follow-up

2025-523280-38-00Thyroid Eye Disease

Amgen Inc.

Eye Diseases

Spain, Poland, France, Italy, Greece

20/05/2026

Phase II

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety and Efficacy of ELV001 as Add-on Therapy in Patients with Active Rheumatoid Arthritis and Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition (START SYNERGY)

2025-524005-32-00Rheumatoid arthritis

Elevara Medicines Limited

Immune System Diseases

Czechia, Bulgaria, Hungary, Netherlands, Poland, Spain

19/05/2026

Phase II

A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of JNJ-95597528 for the Treatment of Adult Participants with Moderate to Severe Atopic Dermatitis

2025-523464-20-00Moderate to Severe Atopic Dermatitis

Janssen Cilag International

Immune System Diseases

Germany, Poland

19/05/2026

Phase II

PODOMOUNT-Basket, a Phase II, multicentre, randomised, 2-arm parallel-group, double-blind, placebo-controlled basket trial to assess safety, tolerability, PK, and efficacy of BI 764198 in four proteinuric kidney diseases

2025-523425-17-00Proteinuric kidney diseases

Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.

Nutritional and Metabolic Diseases

Portugal, Greece, Italy, Poland, Estonia, Slovakia, Sweden, Denmark, Belgium, Norway, Romania, France, Spain, Germany, Netherlands, Croatia

19/05/2026

Phase II

Beamion 44: A randomized, open-label, multi-center Phase IIa platform trial to evaluate the safety and tolerability of zongertinib plus Pt-doublet with or without pembrolizumab (and potential other combinations) in treatment-naïve patients with locally advanced/metastatic non-squamous NSCLC with activating HER2 mutations

2025-523567-38-00locally advanced or metastatic NSCLC

Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.

Neoplasms

Germany, France, Spain

19/05/2026

Phase II

A Phase II Study of Naxitamab Added to Induction Therapy for Subjects with Newly Diagnosed High-Risk Neuroblastoma

2025-524140-35-00Neuroblastoma or ganglioneuroblastoma (nodular or intermixe…

Fundacio Sant Joan De Deu

Neoplasms

Spain

19/05/2026

Phase II

An Open-label, Single-arm, Global Study of Perioperative Durvalumab With Cisplatin-based Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)

2024-519246-75-01Patients With Muscle-Invasive Bladder Cancer

AstraZeneca AB

Neoplasms

Italy, Spain, France, Netherlands

19/05/2026

Phase II

A Phase II, Open-Label Randomized Study of Intravenous Tambiciclib in Combination with the Standard of care Venetoclax and Azacitidine in Patients with Newly Diagnosed AML Who Failed to Achieve at Least MLFS After the First Two Cycles of Treatment with Venetoclax and Azacitidine Alone

2025-524308-31-00Acute myeloid leukemia

DrugsAzacitidine·Venetoclax

Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l., IIS La Fe

Neoplasms

Italy, Spain

19/05/2026

Phase II

INCREDIBLE: INCREmental DIalysis and diet for a Better Life Experience; Clinical relevance of an “add-on” Ketosteril supplementation on incremental haemodialysis period in incident haemodialysis patients. An exploratory randomized controlled trial

2025-524093-41-00Incremental Haemodialysis

Centre Hospitalier Le Mans

Nutritional and Metabolic Diseases

France

18/05/2026

Phase II

A Phase 2a, Randomized, Open-Label, Active-Controlled, Crossover Study to Evaluate Safety and Explore Efficacy of Different Doses of New Lipase NHS7108 Administered Orally in Participants with Exocrine Pancreatic Insufficiency.

2025-521816-20-00Exocrine Pancreatic Insufficiency

DrugZenpep

Aimmune Nestle Health Science US R&D LLC

Nutritional and Metabolic Diseases

Poland, Hungary, Spain, Bulgaria, Italy

18/05/2026

Phase II

Multicentre study evaluating the efficacy of a 7-day course of doxycycline for the treatment of asymptomatic anal lymphogranuloma venereum SHORT-LGV

2025-524978-42-00Asymptomatic anal LGV infection

DrugDoxycycline

Centre Hospitalier Universitaire De Bordeaux

Bacterial Infections and Mycoses

France

18/05/2026

Phase II

TAILOR-PANC: Molecularly Tailored Therapy versus Standard Care in Advanced Pancreatic Cancer (DPCG-02)

2025-522431-34-00Advanced pancreatic cancer

DrugsPemigatinib·Vismodegib·Larotrectinib·Erlotinib

Region Hovedstaden

Neoplasms

Denmark

18/05/2026

Phase II

A Phase 2 Study to Evaluate the Safety and Efficacy of Telisotuzumab Adizutecan for the Treatment of Subjects with Locally Advanced or Metastatic Solid Tumors that Harbor MET Amplification

2024-518871-74-00Locally Advanced or Metastatic Solid Tumours that harbour M…

AbbVie Deutschland GmbH & Co. KG

Neoplasms

Spain, France, Denmark

18/05/2026

Phase II

THRILL: Treat Hyperinflammation in child oncology study - A single arm, historically controlled, open label phase II study on the efficacy and safety of the recombinant interleukin (IL)-1R antagonist anakinra in pediatric cancer patients admitted to the intensive care with sepsis and signs of hyperinflammation

2025-524541-27-00Hyperinflammation, Sepsis

DrugAnakinra

Prinses Maxima Centrum voor Kinderoncologie B.V.

Immune System Diseases

Netherlands

18/05/2026

Phase II

A phase II, multicenter, open-label, single arm study to evaluate the safety and efficacy of asciminib in pediatric participants newly diagnosed or previously treated with Philadelphia positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) with or without known T315I mutation

2025-522138-29-00Philadelphia positive Chronic Myeloid leukemia in Chronic P…

Novartis Pharma AG

Neoplasms

Spain, France, Germany, Poland, Italy, Netherlands, Greece, Hungary

18/05/2026

Phase II

SISTAR: Stratifying Immunosuppression to Allogenic Risk. A randomized, open label, assessor blinded, controlled, non-inferiority, safety study of half- vs standard dose immunosuppression in kidney transplant recipients with a well-matched donor.

2025-525091-29-00Kidney Transplant Recipient

DrugBelatacept

Medical University Of Vienna

Surgical Procedures, Operative

Austria

17/05/2026

Phase II

A Phase 2, Open-label Study of JNJ-79635322 in Participants with Relapsed or Refractory Multiple Myeloma (RRMM) who Have Received at least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti-CD38 Antibody

2025-521976-80-00Relapsed or Refractory Multiple Myeloma (RRMM)

Janssen Cilag International

Neoplasms

Poland, Italy

14/05/2026

Phase II

Open-Label Extension Study to Provide Access to ATH434 in Patients with Multiple System Atrophy

2025-524317-88-00Multiple System Atrophy

Alterity Therapeutics Limited

Nervous System Diseases

France

13/05/2026

Phase II

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of ICP-332 in Participants with Prurigo Nodularis

2025-523404-74-00Prurigo Nodularis

Innocare Pharma Inc.

Skin and Connective Tissue Diseases

Belgium, Poland, Germany, France, Austria

13/05/2026

Phase II

SCARFREE-001: A Phase 2 Dose-Finding and Proof-of-Concept Study of Intradermal Verteporfin for Scar Prevention in Open and Closed Surgical Wounds

2025-525083-14-00Scar formation following surgical wounds

DrugVerteporfin

Odense University Hospital

Therapeutics

Denmark

13/05/2026

Phase II

A Phase 2 Open-Label, Umbrella Platform Design Study of Investigational Agent(s) in Participants With 2L/3L Unresectable Locally Advanced or Metastatic Esophageal Cancer: KEYMAKER-U06 Substudy 06F

2026-525213-31-00Esophageal squamous cell carcinoma

DrugIfinatamab Deruxtecan

Merck Sharp & Dohme LLC

Neoplasms

Czechia, Germany, France, Norway

12/05/2026

Phase II

Maintenance AVElumab after SECond line platinum-based chemotherapy for metastatic urothelial carcinoma: AVESEC trial - GOIRC-02-2025

2025-524077-16-00metastatic urothelial carcinoma

DrugAvelumab

G.O.I.R.C. Gruppo Oncologico Italiano Di Ricerca Clinica

Neoplasms

Italy

12/05/2026

Phase II

A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors

2025-523895-22-00Non-small cell lung cancer (NSCLC), Cervical cancer (CC), M…

DrugsBNT324·Pumitamig

Dualitybio Inc.

Neoplasms

Italy, Poland, France, Spain, Germany

12/05/2026

Phase II

Evaluation of hANP for prevention of acute kidney injury after cardiac surgery: A two-part randomized controlled trial with open-label extension in children aged 0–12 months.

2025-524069-26-00Acute kidney injury (AKI) occurring in newborns and infants…

Vaestra Goetalandsregionen

Therapeutics

Sweden

11/05/2026

Phase II

FINACCESS - Finnish National Study for Early Access to Cancer Therapies

2025-524769-26-00Cancer

HUS-yhtymae

Neoplasms

Finland

08/05/2026

Phase II

A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 250 mg lebrikizumab in patients with localized scleroderma (LEMO)

2025-524435-39-00Localized Scleroderma

DrugLebrikizumab

Charite Universitaetsmedizin Berlin KöR

Skin and Connective Tissue Diseases

Germany

08/05/2026

Phase II

A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Dose-Range Finding Study of ORKA-001 in Participants with Moderate-to-Severe Plaque Psoriasis

2025-523797-17-00Moderate-to-Severe Plaque Psoriasis

Oruka Therapeutics Inc.

Skin and Connective Tissue Diseases

Germany, Spain

08/05/2026

Phase II

Neoadjuvant Immunotherapy and Organ-sparing Treatment in Patients with Stage I-III dMMR Colon Cancer: A National, Multicentre, Personalised, Phase II Study (RESET C2)

2026-525214-62-00Localised dMMR Colon Cancer

DrugPembrolizumab

Region Sjaelland

Digestive System Diseases

Denmark

07/05/2026

Phase II

A prospective, multinational, multicenter, randomized, sequential, double-blind, placebo-controlled, phase 2a clinical study to assess the safety and pharmacokinetics (PK) of OMN6 in hospital-acquired bacterial pneumonia (HABP) or ventilated-associated bacterial pneumonia (VABP) caused by Acinetobacter baumannii complex (ABC).

2025-524200-29-00Hospital-acquired bacterial pneumonia or ventilated-associa…

Omnix Medical Ltd.

Respiratory Tract Diseases

Italy, Hungary, Greece

06/05/2026

Phase II

A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Multicenter Trial Evaluating the Effects of Two Dosing Regimens of Nolasiban on Uterine Contractility and Endocrine Parameters

2025-524896-22-00Women with an indication for IVF/ICSI

ReproNovo ApS

Female Urogenital Diseases and Pregnancy Complications

Spain

06/05/2026

Phase II

A Master Protocol of an Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumour Activity of Novel Combinations in Participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (LIBRA)

2025-524843-11-00Non-Small Cell Lung Cancer

AstraZeneca AB

Neoplasms

France, Italy, Spain

06/05/2026

Phase II

A Phase II, Multi-Center, Master Protocol to Evaluate the Efficacy and Safety of Volrustomig as Monotherapy or in Combination with Anti-cancer Agents in Participants with Advanced/Metastatic Solid Tumors (eVOLVE-02)

2025-523947-36-00Sub-study 4: Esophageal Squamous Cell Carcinoma (Volrustomi…

AstraZeneca AB

Neoplasms

Italy, Germany

05/05/2026

Phase II

A Long-Term Extension Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Patients With Graves' Disease

2025-524001-33-00Graves’ Disease

Immunovant Sciences GmbH

Immune System Diseases

Italy, Greece, Germany, Hungary, Poland, Czechia, Netherlands, Spain, Belgium, Bulgaria, Latvia

05/05/2026

Phase II

A randomized, double masked, placebo-controlled, multicenter, dose-range finding study to assess the efficacy and safety of FWY003 in patients with geographic atrophy secondary to age-related macular degeneration

2025-523704-77-00Geographic atrophy secondary to age-related macular degener…

Novartis Pharma AG

Eye Diseases

Bulgaria, Romania, Germany, Czechia, Spain, Poland, Italy, Hungary, France

04/05/2026

Phase II

Randomised, placebo-controlled, double-blind, parallel-group Phase II study to evaluate the efficacy and safety of oral BI 3000202 in patients with moderate to severe systemic lupus erythematosus (SLE)

2025-523488-39-00Systemic lupus erythematosus

Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.

Immune System Diseases

Bulgaria, Romania, Germany, Spain, Hungary, Poland, Croatia, Netherlands

04/05/2026

Phase II

Antidepressant effects of psilocybin in the absence of serotoninergic psychedelic experience: a dimensional functional neuroimaging approach

2025-521690-14-00Major depressive disorder

Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau

Mental Disorders

Spain

04/05/2026

Phase II

Staphylococcus aureus Network Adaptive Platform trial (SNAP)

2025-521388-11-00Staphylococcus aureus bacteraemia

Fundacion Para La Gestion De La Investigacion En Salud De Sevilla

Bacterial Infections and Mycoses

Spain

04/05/2026

Phase II

"Contribution of 68Ga-FAPI-46 PET-CT in the initial staging of gastric cancers eligible for curative treatment" "FAPGASTRO"

2025-524434-25-00gastric cancer

Drug[68Ga]Ga-FAPI-46

Centre Hospitalier Universitaire De Bordeaux

Neoplasms

France

30/04/2026

Phase II

Impact of epilepsy on the brainstem adenosine pathway and its relation with arousal and respiratory reactivity BRAVE

2025-524511-36-00Neurology

Hospices Civils De Lyon

Nervous System Diseases

France

30/04/2026

Phase II

GLO-Surgery: Indocyanine Green and near infrared fLuorescence in paediatric Oncology surgery

2024-514089-37-00Patients with pulmonary metastasis from any primary tumour,…

The University Of Birmingham

Neoplasms

Netherlands

30/04/2026

Phase II

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Psoriatic Arthritis.

2025-520997-21-00Psoriatic arthritis

Merck Sharp & Dohme LLC

Musculoskeletal Diseases

Poland, Germany, Spain

30/04/2026

Phase II

A Phase 2a, Randomized, Participant- and Investigator blinded, Parallel-group, Placebo-controlled, Multicenter Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults with DSM-5 Schizophrenia (STAR-1)

2025-524058-32-00Schizophrenia

Novartis Pharma AG

Mental Disorders

Bulgaria

29/04/2026

Phase II

Efficacy of cell therapy with allo-MSCs in patients with gvhd resistant to ruxolitinib second line therapy: a Phase IIB Clinical Trial - MSC-GRR2 Study

2025-523448-10-00Gvhd Resistant to ruxolitinib and steroids

Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia

Hemic and Lymphatic Diseases

Italy

28/04/2026

Phase II

A Phase 2 Study of [68Ga]BED003 for PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications

2025-521983-36-00Colorectal cancer (CRC), gastric cancer (GC), pancreatic du…

Blue Earth Diagnostics Ireland Limited

Neoplasms

Netherlands, Italy

28/04/2026

Phase II

Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety of Anumigilimab (CSL324) in Adults with Sickle Cell Disease

2025-521154-42-00Sickle Cell Disease

CSL Behring LLC

Hemic and Lymphatic Diseases

Belgium, Netherlands, France, Italy

28/04/2026

Phase II

Electrophysiological analysis of Gamma-Hydroxybutyrate-induced sleep in intensive care patients: A Pilot Double-Blind Randomized Controlled Trial.(GAMMA-SLEEP)

2025-521967-11-00The study population includes adult ICU patients with a hos…

DrugNaCl

Assistance Publique Hopitaux De Paris

Mental Disorders

France

28/04/2026

Phase II

A phase II, double-blinded, placebo-controlled, clinical trial to determine the efficacy and safety of AP707 in the treatment of Borderline Personality Disorder.

2024-510873-11-00Borderline personality disorder

Apurano Pharmaceuticals GmbH

Mental Disorders

Germany

28/04/2026

Phase II

A Phase IIb, multicentre, randomised, doubleblind, placebocontrolled, three-arm parallel-group study to evaluate the efficacy, safety, and tolerability at Week 24 of 2 doses of CHF10067 (zampilimab) in participants with idiopathic pulmonary fibrosis

2024-514246-37-00Idiopathic pulmonary fibrosis (IPF)

Chiesi Farmaceutici S.p.A.

Respiratory Tract Diseases

Belgium, Germany, Italy, Czechia, Bulgaria, Netherlands, France, Portugal, Poland, Spain, Romania

27/04/2026

Phase II

A randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and quality of life outcomes of Vi-Siblin in patients with low anterior resection syndrome following rectal cancer surgery.

2024-514541-11-00Low anterior resection syndrome after low anterior resectio…

Sykehuset Telemark HF

Digestive System Diseases

Norway

27/04/2026

Phase II

Methylphenidate for Early Awakening in Coma (MEAWAKE)

2025-524937-19-00Coma due to acute brain injury

DrugMethylphenidate

Rigshospitalet

Nervous System Diseases

Austria, Denmark, Germany, France

27/04/2026

Phase II

The MAVRiC Study: A Phase II Study of Disease Risk Mutation-guided Finite Duration Acalabrutinib plus Venetoclax for Relapse in CLL/SLL after First-line Finite covalent BTKi plus BCL2i combination, with or without Obinutuzumab

2024-518858-17-00Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CL…

DrugsAcalabrutinib·Venetoclax

AstraZeneca AB

Neoplasms

Italy, Austria, Spain, Ireland, Czechia, Poland

27/04/2026

Phase II

Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of MRM-3379 in Male Participants with Fragile X Syndrome

2025-523738-21-00Fragile X Syndrome

Mirum Pharmaceuticals Inc.

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Spain

27/04/2026

Phase II

Diving into the noradrenergic system : Role of the alpha2C-adrenergic receptors NA2C-TEP-IRM

2025-524602-15-00Neurology

Hospices Civils De Lyon

Nervous System Diseases

France

24/04/2026

Phase II

Prevention of Sexual Offending with Cognitive Behavioral Therapy Alone Versus Therapy Combined with Testosterone Suppression – the PREVENT-MED randomized clinical trial

2024-518120-68-01Paraphilic disorder, Compulsive sexual behavior disorder

DrugsTestosterone·Degarelix

Vaestra Goetalandsregionen

Mental Disorders

Sweden

24/04/2026

Phase II

A randomized phase 2 trial of neoadjuvant pembrolizumab plus belzutifan with or without lenvatinib in patients with localized renal cell carcinoma. The moonlanding trial

2024-519673-18-00Patients with localized renal cell carcinoma

DrugsBelzutifan·Lenvatinib·Pembrolizumab

Vall D Hebron Institute Of Oncology

Neoplasms

Spain

24/04/2026

Phase II

Curing HIV: proof of concept randomized clinical trial with Pyrimethamine, Lenalidomide, TOpiramate (PLUTO)

2026-525211-14-00HIV-1

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Virus Diseases

Netherlands

24/04/2026

Phase II

Mechanisms of Resistance to anti-PD-1 Therapy in cutaneous Squamous Cell Carcinomas: Impact of Tumor Cell Plasticity on Promoting Myeloid Suppressor Cell Infiltration. A phase II single arm, unicenter study of cemiplimab in patients with locally advanced cSCCs.

2025-524255-32-00Cutaneous squamous cell carcinoma (ccSCC)

DrugCemiplimab

Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIBELL

Neoplasms

Spain

24/04/2026

Phase II

Colchicine to Quench the Inflammatory Response after Deep Vein Thrombosis: The CONQUER-DVT Randomized Controlled Trial

2025-521836-12-00deep vein thrombosis

Universita' Degli Studi G. D'Annunzio Di Chieti

Hemic and Lymphatic Diseases

Italy

23/04/2026

Phase II

A randomized controlled, two-arm (1:1 ratio) Phase IIa trial to assess the efficacy and safety of obinutuzumab in treating adults with de novo minimal change disease

2025-520641-69-00Kidney disease

DrugsTacrolimus·Prednisolone·Obinutuzumab·Prednisone

Medizinische Universitaet Innsbruck

Immune System Diseases

Germany, Austria, France

23/04/2026

Phase II

A Multicentre, Parallel-group, Phase II, Randomised, Double-blind, 4 Arm Study to Evaluate Efficacy and Safety of AZD1163 in Participants with Moderately-to-Severely Active Rheumatoid Arthritis (LaunchPAD-RA)

2025-522076-85-00Rheumatoid arthritis

AstraZeneca AB

Immune System Diseases

Hungary, Spain, Bulgaria, Germany, Poland

22/04/2026

Phase II

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Finding Study of CX11 Tablets in Patients with Type 2 Diabetes Mellitus.

2025-524514-28-00Type 2 Diabetes Mellitus

Corxel Pharmaceuticals Inc.

Nutritional and Metabolic Diseases

Poland

22/04/2026

Phase II

A phase II trial evaluating treatment intensification with Ezabenlimab in patients with PD-L1–expressing, locally advanced head and neck squamous cell carcinoma (LA-HNSCC) with minimal residual disease (MRD) as detected by circulating tumor DNA (ctDNA) after curative-intent chemoradiation

2025-523575-36-00Locally advanced head and neck squamous cell carcinoma (LA-…

DrugEzabenlimab

Cliniques Universitaires Saint-Luc

Neoplasms

Belgium

22/04/2026

Phase II

NoELA_No Endocrine therapy in small HR+ HER2- low relapse risk Luminal A early breast cancer, a single-arm de-escalation trial

2025-523683-20-00Postmenopausal patients with small (pT1a-b pN0) hormone rec…

DrugsTamoxifen·Exemestane·Anastrozole·Letrozole

Unicancer

Neoplasms

France

21/04/2026

Phase II

Albuminuria Reduction Trial and Investigation with Survodutide Treatment in CKD (ARTIST-CKD)

2025-525068-13-00Chronic Kidney Disease

DrugSurvodutide

Universitair Medisch Centrum Groningen

Nutritional and Metabolic Diseases

Germany, Spain, Netherlands

21/04/2026

Phase II

Protocol Title: Efficacy and safety of once-weekly subcutaneous NNC0662-0419 in participants with type 2 diabetes – a dose-finding study

2025-523260-20-00type 2 diabetes

DrugSemaglutide

Novo Nordisk A/S

Hormonal diseases

Spain, Hungary, Portugal, Poland, Slovakia, Croatia

21/04/2026

Phase II

A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study of the Efficacy and Safety of Vamifeport in Adult Subjects with HFE-related Hereditary Hemochromatosis (FERROCLEAR Study)

2025-523793-16-00Homeostatic iron regulator gene-related hereditary hemochro…

CSL Behring LLC

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Austria, Poland, Spain, Germany, France, Ireland, Romania, Belgium, Italy, Czechia, Netherlands

20/04/2026

Phase II

A randomized phase II study comparing the safety and efficacy of mifamurtide and standard therapy containing sorafenib in pediatric and young adult patients with high-risk osteosarcoma

2026-525223-24-00Relapsed/refractory osteosarcoma, High-grade osteosarcoma

Instytut Matki I Dziecka

Neoplasms

Poland

20/04/2026

Phase II

An autologous and antigen-specific cell-based therapy of vitamin D3-treated and myelin-derived peptide loaded tolerogenic dendritic cells in subjects with progressive forms of multiple sclerosis: a phase IIa, open-label, self-controlled, multi-center clinical trial.

2025-522040-40-01Multiple Sclerosis

Universitair Ziekenhuis Antwerpen, Hospital Germans Trias I Pujol

Immune System Diseases

Belgium, Spain

20/04/2026

Phase II

IFCT-2502 LIMPID Phase II trial assessing 1st line and 2nd line treatment in patients with advanced Non-Small Cell Lung Cancer and Interstitial Lung Disease

2025-522790-10-00Non Small Cell Lung Cancer, Interstitial Lung Disease

Intergroupe Francophone De Cancerologie Thoracique

Neoplasms

France

17/04/2026

Phase II

A Multicentre, Open-Label Study Evaluating the Safety, Tolerability and Efficacy of MaaT013 in Ruxolitinib-Refractory or Intolerant Paediatric and Adolescent participants with Gastrointestinal Acute Graft-versus-Host Disease

2025-524302-15-00Gastrointestinal Acute Graft-versus-Host Disease (GI-aGvHD)

DrugVancomycin

MaaT PHARMA

Digestive System Diseases

Netherlands, Italy, France, Spain

17/04/2026

Phase II

Omalizumab for monotherapy treatment of patients with food allergies to plant-based foods due to sensitization to LTP and profilin

2025-524629-42-00Categoria 2, Patients with vegetable allergies due to sensi…

DrugOmalizumab

Fundacion Publica Andaluza Para La Investigacion De Malaga En Biomedicina Y Salud

Not possible to specify

Spain

17/04/2026

Phase II

METAREM / META-1 - METAREM : Adaptive Master Trial for Advanced Cancers with Rapid Evaluation of Molecular & Immune Status for Stratified Immunotherapies in Oncology / META-1 : Anti-PD1 monotherapy in 1L advanced NSCLC patients with PDL1 TPS > 50% and PTI=0

2025-522655-26-00METAREM:Patients with advanced cancer, as defined as unrese…

Unicancer

Neoplasms

France

16/04/2026

Phase II

A single arm phase II study evaluating intracranial efficacy of tarlatamab in patients with asymptomatic active brain metastases from small cell lung cancer

2025-522162-75-00patients with asymptomatic active brain metastases from sma…

Academisch Ziekenhuis Maastricht

Respiratory Tract Diseases

Netherlands

15/04/2026

Phase II

Phase 2, Open-Label, Long-Term, Extension (OLE) Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children with Hypochondroplasia: ACCEL OLE

2025-523509-13-00Hypochondroplasia

Qed Therapeutics Inc.

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Spain, Norway

15/04/2026

Phase II

Double-T - Improving outcomes in high-risk 2nd line relapsed/refractory Large B-Cell Lymphoma patients eligible for CAR-T-cell therapy with a Glofitamab-based induction and consolidation concept

2025-523806-34-00relapsed/refractory Large B-Cell Lymphoma

Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Hemic and Lymphatic Diseases

Germany

15/04/2026

Phase II

68Ga-FAPI-46 PET for Giant Cell Arteritis-Polymyalgia Rheumatica Spectrum Disease

2024-511977-31-01giant cell arteritis - polymyalgia rheumatica spectrum dise…

Drug[68Ga]Ga-FAPI-46

Universitair Medisch Centrum Groningen

Cardiovascular Diseases

Netherlands

14/04/2026

Phase II

Randomized, Double-Blinded, Vehicle-Controlled, Parallel Group, Adaptive Proof-of-concept, Dose-selecting Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Intranasal Cenegermin (recombinant human Nerve Growth Factor [rhNGF]) in Adult Participants with subacute moderate to severe Traumatic Brain Injury (TBI).

2025-522692-29-00Subacute Moderate to Severe Traumatic Brain Injury (TBI)

DrugCenegermin

Dompe' Farmaceutici S.p.A.

Nervous System Diseases

Italy, Denmark, Finland, France, Germany, Spain, Sweden, Poland

14/04/2026

Phase II

A Phase 2, Open-label, Multicohort, Study of Rinatabart Sesutecan (Rina-S) in Participants with Non-Small Cell Lung Cancer

2025-522107-18-00Locally advanced or metastatic Non-Small Cell Lung Cancer

DrugPegfilgrastim

Genmab A/S

Neoplasms

Germany, Hungary, Netherlands, France, Italy, Belgium, Spain, Poland

14/04/2026

Phase II

Teclistamab plus autologous lymphocytes infusion for the treatment of relapsed/refractory Multiple Myeloma (TALIM). MM0125

2025-521827-61-00refractory/relapsed multiple myeloma

DrugTeclistamab

Fondazione G.I.M.Em.A Franco Mandelli Ets

Hemic and Lymphatic Diseases

Italy

14/04/2026

Phase II

Standardized Phleum pratense in TBU/ml in liquid formulation for sublingual immunotherapy: Phase II, randomized dose determination clinical trial. DEDO-G Study.

2025-522730-31-00Allergic rhinitis/rhinoconjunctivitis caused by grass polen…

Asac Pharmaceutical Inmunology S.A.

Immune System Diseases

Spain

14/04/2026

Phase II

A phase II, multicenter study of GlOfitamab in patients with mantle cell Lymphoma and inaDequate response or relapse following CAR T-cell therapy (GOLD)

2025-523428-39-00Mantle Cell Lymphoma

Fondazione Italiana Linfomi Ets

Hemic and Lymphatic Diseases

Italy

14/04/2026

Phase II

C6231002 - A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF 08049820 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS

2025-522965-31-00Atopic Dermatitis

Pfizer Inc.

Skin and Connective Tissue Diseases

Poland, Czechia, Germany, Bulgaria, France

14/04/2026

Phase II

A randomized, placebo-controlled trial to assess the efficacy, tolerability, and pharmacokinetics of clemastine in children and adults with Pitt-Hopkins syndrome

2025-524195-29-00Pitt-Hopkins syndrome

Amsterdam UMC Stichting

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Netherlands

13/04/2026

Phase II

A Phase 2, multicenter, open label, non-randomized study to evaluate the efficacy and safety of extended dosing of belantamab mafodotin in different combinations with standard of care regimens in participants with relapsed-refractory multiple myeloma (DREAMM-15)

2025-523117-28-00Relapsed or Refractory Multiple Myeloma

Glaxosmithkline Research & Development Limited

Neoplasms

France, Germany, Greece, Netherlands, Spain

13/04/2026

Phase II

Randomized adaptive assessment of post COVID syndrome treatments (RAPID): Evaluating the Efficacy of Bupropion for the Treatment of Post-COVID-19 Syndrome-associated Fatigue (ELAPSE)

2025-524443-12-00Post Covid Syndrome (PCS)

Goethe University Frankfurt

Virus Diseases

Germany

13/04/2026

Phase II

A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Intra-Articular Allocetra in Patients with Primary Knee Osteoarthritis

2025-524668-39-00Knee Osteoarthritis

Enlivex Therapeutics Ltd.

Musculoskeletal Diseases

Denmark, Poland

13/04/2026

Phase II

A Phase 2b, Randomized, Double blind, Placebo controlled, Parallel group, Multicenter, Dose ranging Study Investigating the Efficacy and Safety Profile of KT-621 Administered Orally to Adult Participants with Uncontrolled Moderate to Severe Eosinophilic Asthma

2025-523180-38-00Uncontrolled Moderate to Severe Eosinophilic Asthma

Kymera Therapeutics Inc.

Immune System Diseases

Spain, Romania, Slovakia, Poland, Germany, Italy, Belgium, Austria

10/04/2026

Phase II

A multicenter phase 2 study of Belantamab mafodotin and Mezigdomide in combination with a phase Ib Safety run in patients with relapsed multiple myeloma following BCMA-targeting CAR-T cells or bispecific antibodies. The IFM 2024-01 clinical trial (BELAMI)

2025-520976-25-00Relapsed/refractory multiple myeloma

DrugMezigdomide

Centre Hospitalier Universitaire De Saint Etienne

Hemic and Lymphatic Diseases

France

09/04/2026

Phase II

Retinoic acid and sperm production in infertile men

2024-519644-33-00oligozoospermia

Les Hopitaux Universitaires De Strasbourg

Not possible to specify

France

09/04/2026

Phase II

A Phase 2 Study to Investigate the Safety and Efficacy of Petosemtamab in Adults with Non-Small Cell Lung Cancer in Combination with Pembrolizumab.

2025-522867-13-00Non Small Cell Lung Cancer

Merus B.V.

Not possible to specify

Spain, Belgium, Netherlands, Poland, Italy, France

09/04/2026

Phase II

A Phase 2, single arm Multicenter, Study testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM). (MEZI-KD)

2025-521090-14-00Patients with relapsed/refractory symptomatic multiple myel…

DrugsMezigdomide·Carfilzomib·Dexamethasone

Assistance Publique Hopitaux De Paris

Hemic and Lymphatic Diseases

France

08/04/2026

Phase II

ETOP 29-25 START-lung: A multicentre phase II trial of tarlatamab in patients with pretreated extensive-stage small cell lung cancer (ES-SCLC) and ECOG PS 2.

2025-522288-13-00Patients with pretreated extensive-stage small cell lung ca…

ETOP IBCSG Partners Foundation

Neoplasms

France, Greece, Spain, Italy

08/04/2026

Phase II

Treatment of low-flow vascular malformations with bleomycin electrosclerotherapy (BEST)

2025-524123-45-00VASCULAR MALFORMATION

Institute Of Oncology Ljubljana

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Slovenia

07/04/2026

Phase II

The NOVA-NOA Trial A Novel Aromatase Inhibitor, Leflutrozole, for Treatment of Non-Obstructive Azoospermia

2025-524774-42-00Male Infertility

Herlev Hospital

Male Urogenital Diseases

Denmark

07/04/2026

Phase II

Randomized, Double-blind, Placebo-controlled, Proof-of-concept Phase II Trial Investigating the Effect of Valproic Acid in Women with Adenomyosis.

2025-523076-23-00Adenomyosis

CCDRD Cooperative Clinical Drug Research and Development AG, Nadezhda Reproductive Science OOD

Female Urogenital Diseases and Pregnancy Complications

Bulgaria

03/04/2026

Phase II

A Phase 2, Multicenter, Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Ublituximab Administered at Various Injection Sites and Relative Bioavailability via Autoinjector Device versus Syringe in Patients with Multiple Sclerosis

2025-523757-33-00multiple sclerosis

Tg Therapeutics Inc.

Nervous System Diseases

Poland

03/04/2026

Phase II

Open-Label, Multi Stage Study to Optimize the Intraputaminal Administration of AB-1005 Using a Prescriptive Infusion Algorithm (PIA)

2025-522441-21-00Parkinson's Disease

Askbio Inc.

Nervous System Diseases

Poland

03/04/2026

Phase II

Efficacy and safety of a novel dual pH-dependent delayed-release ColeseveLam for the trEatment of bile Acid diarrhoea: a Randomized, double-blind, parallel-group, placebo-controlled clinical trial - CLEAR

2025-523868-20-00Bile acid diarrhoea

Monteresearch S.r.l.

Digestive System Diseases

Italy

02/04/2026

Phase II

TREAT-EC (Tirzepatide in the treatment of endometrial cancer) - a clinical trial

2025-523877-40-00Endometrial adenocarcinoma

DrugsLevonorgestrel·Tirzepatide

University College Dublin

Neoplasms

Ireland

02/04/2026

Phase II

Colonic Intramural Injections of Botulin toxin versus placebo to treat fragmented defecation and urgency after restorative total mesorectal excision (TME) for rectal cancer

2025-524342-96-00Rectal Cancer

DrugBotulinum toxin type A

UZ Leuven

Digestive System Diseases

Belgium

02/04/2026

Phase II

Open-label, safety, tolerability and proof of concept study to evaluate the use of ANXV (recombinant human Annexin A5 protein) in the treatment of patients with either Diabetic Retinopathy or recent onset Retinal Vein Occlusion

2026-525349-65-00Diabetic Retinopathy, Retinal Vein Occlusion

Annexin Pharmaceuticals AB (publ)

Eye Diseases

Germany

02/04/2026

Phase II

L-Thyroxine for the treatment of acute unilateral vestibulopathy (AUVP): a monocentric, double-blind, placebo-controlled trial (T4U)

2024-519515-34-00Patients with acute unilateral vestibulopathy (AUVP)

Klinikum der Universitaet Muenchen AöR

Nervous System Diseases

Germany

02/04/2026

Phase II

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy and Safety of surlorian (ARM210, S48168) in Adults with Autosomal Dominant RYR1-Related Myopathy

2025-522343-18-00Autosomal Dominant RYR1-Related Myopathy

Rycarma Therapeutics Inc.

Musculoskeletal Diseases

Netherlands, Spain, France, Germany

02/04/2026

Phase II

A Phase 2, randomized, placebo-controlled, double-blind clinical study to evaluate efficacy and safety of LAD328 in adult subjects with moderate to severe hidradenitis suppurativa

2025-521865-29-00moderate-to-severe hidradenitis suppurativa

Almirall S.A.

Skin and Connective Tissue Diseases

Bulgaria, Spain, France, Poland, Germany

01/04/2026

Phase II

A multicenter, multicohort, phase 2 platform trial to personalize second-line treatment intensity and targeting in HR-positive, HER2-negative metastatic breast cancer through an integrated liquid biopsy algorithm.

2025-523460-21-00Metastatic breast cancer

DrugsCapivasertib·Elacestrant·Trastuzumab deruxtecan·Fulvestrant

Centro Di Riferimento Oncologico Di Aviano

Neoplasms

Italy

31/03/2026

Phase II

A Phase 2, Dose Ranging, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of BFB759 in Patients with Moderate to Severe Hidradenitis Suppurativa (COMPASS 2 - HS)

2025-522440-41-00Hidradenitis Suppurativa

Bluefin Biomedicine Inc.

Immune System Diseases

Spain, Germany, Czechia, Poland, Bulgaria

31/03/2026

Phase II

OmaMig Pilot: An open-label, phase IIa, single arm pilot study evaluating the potential clinical benefit and safety of omalizumab in adults with episodic migraine.

2025-522448-41-00Episodic migraine

DrugOmalizumab

Oslo University Hospital HF

Nervous System Diseases

Norway

31/03/2026

Phase II

A randomized, double-blind, placebo-controlled trial of semaglutide for reducing cannabis use in adults with cannabis use disorder

2025-524163-21-00Cannabis dependence (Cannabis Use Disorder or CUD)

Region Hovedstaden

Behavior and Behavior Mechanisms

Denmark

30/03/2026

Phase II

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy, Safety and Tolerability of Lesigercept in Adult Patients with Chronic Spontaneous Urticaria Who Are Inadequately Controlled by H1-Antihistamines (CLEAR)

2025-524006-14-00Chronic Spontaneous Urticaria

Yuhan Corp.

Skin and Connective Tissue Diseases

Bulgaria, Poland

27/03/2026

Phase II

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Proof of Concept (POC) Study Evaluating the Safety, Tolerability, and Efficacy of Nintedanib Solution for Inhalation (AP02) in Participants with Idiopathic Pulmonary Fibrosis (IPF) (AURA-IPF)

2025-523431-19-00Idiopathic Pulmonary Fibrosis (IPF)

Avalyn Pharma Inc.

Respiratory Tract Diseases

Germany, Italy, Spain, Ireland

26/03/2026

Phase II

PNOC029_Tovorafenib for the treatment of newly diagnosed or recurrent craniopharyngioma in children and young adults

2024-511510-20-00craniopharyngioma

DrugTovorafenib

Prinses Maxima Centrum voor Kinderoncologie B.V.

Neoplasms

Netherlands, France, Germany

25/03/2026

Phase II

A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study of NAV-240 in Adult Participants with Moderate-to-Severe Hidradenitis Suppurativa

2025-523557-33-00Moderate-to-Severe Hidradenitis Suppurativa

Navigator Medicines Inc.

Skin and Connective Tissue Diseases

Hungary, Poland, Germany, Bulgaria, Romania

25/03/2026

Phase II

An Open-label, Multi-center, Global Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC)

2025-523803-31-00Advanced non-small cell lung cancer (NSCLC)

Shanghai Henlius Biotech Inc.

Therapeutics

Italy, Romania, Poland, Spain, France

25/03/2026

Phase II

A Phase 2, randomized, placebo-controlled, double-blind clinical study to evaluate efficacy and safety of LAD603 in adult subjects with severe to very severe alopecia areata

2025-523342-27-00Alopecia areata

Almirall S.A.

Skin and Connective Tissue Diseases

Bulgaria, Romania, Poland, Germany, Spain

24/03/2026

Phase II

The efficacy of oral vancomycin therapy in managing different phenotypes of paediatric inflammatory bowel diseases by correlating treatment response to commensal microbiota composition and function (VERDA)

2025-524543-12-00Ulcerative colitis

DrugVancomycin

Pirkanmaan hyvinvointialue

Digestive System Diseases

Finland

24/03/2026

Phase II

MitOxyVit: Mitochondrial network modulation approach using hyperbaric oxygen (HBO) therapy and NNbUVB for treating vitiligo

2025-524709-34-00Vitiligo

Centre Hospitalier Universitaire De Nice

Skin and Connective Tissue Diseases

France

24/03/2026

Phase II

CHARACTERIZATION OF ASTROCYTE REACTIVITY WITH [18F]F-DED PET IN NEURODEGENERATIVE DISEASES

2025-523284-37-00Dementia, Autosomal Dominant Alzheimer's Disease, Sporadic …

Barcelonabeta Brain Research Center

Nervous System Diseases

Spain

24/03/2026

Phase II

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of V940 in Combination With Pembrolizumab and Chemotherapy as First-Line Treatment for Participants With Metastatic Squamous NSCLC (INTerpath-013)

2025-520902-37-00Non-small cell lung cancer stage IV

Merck Sharp & Dohme LLC

Neoplasms

Italy, Spain, Poland, France

23/03/2026

Phase II

Comparative Study on the Mode of Action of Vicadrostat and Spironolactone on Protein Profiles and Renal Hemodynamic Effects in Patients with Heart Failure or Cardiovascular Disease and Chronic Kidney Disease (COMPARE-VS)

2025-523743-35-00Heart failure, cardiovascular disease, chronic kidney disea…

Universitair Medisch Centrum Groningen

Cardiovascular Diseases

Netherlands

23/03/2026

Phase II

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib plus Ribociclib plus Fulvestrant Versus Placebo plus Ribociclib plus Fulvestrant in Patients with Endocrine-Resistant Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer with Chromosome 8P Loss and Without a PIK3CA Mutation

2025-523013-28-00Endocrine-Resistant Hormone-Receptor-Positive, HER2-Negativ…

F. Hoffmann-La Roche AG

Neoplasms

France, Italy, Poland, Germany, Spain

23/03/2026

Phase II

A Phase 2 Study of ACR-368 Therapy in Subjects with Endometrial Cancer

2025-524542-10-00Endometrial cancer

Acrivon Therapeutics Inc.

Neoplasms

Italy, Germany, Spain, France

23/03/2026

Phase II

A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117570 in Adults with Schizophrenia Who Warrant Inpatient Hospitalization

2025-521868-35-00Schizophrenia

Neurocrine Biosciences Inc.

Mental Disorders

Romania, Poland, Bulgaria, Croatia

23/03/2026

Phase II

A Randomized, Single-Blind, Fixed-Order Crossover Study to Assess the Effects of CSX-1004 Injection on Fentanyl-Induced Respiratory Depression in Healthy Adult Subjects and Subjects with Opioid Use Disorder

2025-524133-33-00Opioid use disorder

Cessation Therapeutics Inc.

Anesthesia and Analgesia

Netherlands

20/03/2026

Phase II

A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants with Active Psoriatic Arthritis

2025-523141-10-00Active Psoriatic Arthritis

Janssen Cilag International

Immune System Diseases

Spain, Poland, Czechia, Germany, Hungary

20/03/2026

Phase II

PAROCAINE : Evaluation of the Clinical Tolerance of an Intra-Parotid Injection of Bupivacaine Combined with Dexamethasone After Parotidectomy for a Benign Tumor – Prospective Single-Center Cohort Study

2025-524358-32-00Indication opératoire validée de parotidectomie partielle p…

Centre Hospitalier Universitaire De Nimes

Otorhinolaryngologic Diseases

France

19/03/2026

Phase II

Boosting osimertinib Blood Brain Barrier penetration in patients with epidermal growth factor receptor mutated non-small cell lung cancer (OSIBBBOOST)

2025-523033-26-00Patients with EGFR-mutated metastatic NSCLC, without CNS me…

DrugsFebuxostat·Osimertinib

Academisch Ziekenhuis Maastricht

Respiratory Tract Diseases

Netherlands

19/03/2026

Phase II

A Phase 2 Posology Study with Long-Term Extension in Participants with Well‑Controlled Recurrent Pericarditis to Evaluate the Efficacy and Safety of Transition Regimens to KPL-387 Monotherapy from Standard Therapies

2025-523234-66-00Well-Controlled Recurrent Pericarditis

Kiniksa Pharmaceuticals GmbH

Therapeutics

Spain, Greece, Germany, France, Italy, Poland

19/03/2026

Phase II

Low-dose versus standard-dose anticoagulation with argatroban or enoxaparin during extracorporeal membrane oxygenation controlled by anti-IIa or anti-Xa assay

2025-524553-13-00lung and/or heart failure

DrugEnoxaparin

Fakultni Nemocnice Ostrava

Cardiovascular Diseases

Czechia

19/03/2026

Phase II

A randomized, double blind, placebo-controlled, phase II, multicentre trial to explore the efficacy and safety of oral AP1189 tablets administered at the dose 100 mg/day for 12 weeks in patients diagnosed with polymyalgia rheumatica and in remission on glucocorticoid

2026-525343-33-00Polymyalgia rheumatica

DrugAP1189

Synact Pharma ApS

Musculoskeletal Diseases

Denmark

19/03/2026

Phase II

SEZanne: A Phase 2 Randomized, Open label, Multicenter Study to Evaluate the Optimal Dose, Safety, and Efficacy of ABBV-706 in Combination with Atezolizumab versus Standard of Care as First-Line Treatment in Subjects with Previously Untreated Extensive Stage Small Cell Lung Cancer (ES-SCLC)

2024-517490-24-00Small Cell Lung Cancer

AbbVie Deutschland GmbH & Co. KG

Neoplasms

Spain, Germany, Italy, Poland, Belgium

18/03/2026

Phase II

J6E-MC-KWAN: A Phase 2, Multicenter, Randomized, Double-Blind, Active-Controlled Study of LY4268989 (MORF-057) Co-Administered with Mirikizumab in Adults with Moderately to Severely Active Ulcerative Colitis

2025-522338-30-00Ulcerative Colitis

Eli Lilly & Co.

Digestive System Diseases

Hungary, Spain, Denmark, Netherlands, Poland, Romania, Germany, Italy, Austria

18/03/2026

Phase II

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamic Effects of REGN13335, an Anti-PDGF-B Monoclonal Antibody, in Adults with Pulmonary Arterial Hypertension

2024-514754-79-00Pulmonary Arterial Hypertension (PAH)

Regeneron Pharmaceuticals Inc.

Cardiovascular Diseases

Latvia, Belgium, France, Poland, Germany, Spain, Czechia

18/03/2026

Phase II

Effect of faecal microbiota transplant on the expression of autism spectrum disorder core symptoms in children – open-label phase II clinical trial (FMT-PAS)

2025-524673-16-00Autism spectrum disorder

DrugFaecal microbiota transplantation

Masarykova Univerzita

Nervous System Diseases

Czechia

17/03/2026

Phase II

An open-label, uncontrolled, multicenter study to assess the effect of zigakibart treatment on histologic, circulating, and excreted markers of kidney disease and dysfunction in adult patients with IgA nephropathy

2024-519699-24-00IgA nephropathy

Novartis Pharma AG

Immune System Diseases

Czechia, Germany, Spain, Italy, Poland

17/03/2026

Phase II

A Phase 2, Randomized, Masked, Placebo-Controlled Study of Subcutaneously Administered ADX-038 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

2025-521779-30-00Geographic atrophy secondary to age-related macular degener…

Adarx Pharmaceuticals Inc.

Eye Diseases

Germany, Portugal, Italy, Spain

17/03/2026

Phase II

SHIELD – Swift Hydrocortisone Intervention after trauma exposure

2025-523350-13-02Posttraumatic Stress Disorder (PTSD)

Amsterdam UMC Stichting

Mental Disorders

Netherlands

17/03/2026

Phase II

An Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of Weekly Intravenous Infusions of BMN 351 in Participants with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

2024-511656-41-00Duchenne Muscular Dystrophy

Biomarin Pharmaceutical Inc.

Musculoskeletal Diseases

Spain, Italy, Netherlands

16/03/2026

Phase II

A Phase 2 Study of Emavusertib in Combination with an Approved Bruton Tyrosine Kinase Inhibitor in Patients with Chronic Lymphocytic Leukemia and Other B-cell Malignancies

2025-523600-68-00Chronic Lymphocytic Leukemia and Other B-cell Malignancies

Curis Inc.

Neoplasms

Spain, Italy

16/03/2026

Phase II

Comparison of esketamine mouthwash versus intravenous administration for the treatment of chemotherapy/radiotherapy-induced mucositis

2025-522545-22-00Oral mucositis

DrugEsketamine

Amsterdam UMC Stichting

Anesthesia and Analgesia

Netherlands

13/03/2026

Phase II

A Phase 2, monocentric, prospective, nonrandomized, open-label, experimental study to evaluate efficacy and safety of intrabronchial instillation of liposomal Amphotericin B in patients with simple pulmonary aspergilloma.

2025-523501-15-00Simple aspergilloma

DrugAmphotericin B

Pauls Stradins Clinical University Hospital

Respiratory Tract Diseases

Latvia

13/03/2026

Phase II

A phase 2b, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of Usnoflast administered to adult subjects with Amyotrophic Lateral Sclerosis (ALS)

2025-522580-15-00Amyotrophic Lateral Sclerosis (ALS)

Zydus Therapeutics Inc.

Nervous System Diseases

Spain, Germany, Sweden, Ireland, Poland, Italy, Belgium, France, Netherlands

12/03/2026

Phase II

A randomized placebo-controlled double-blind trial phase II two-arm study to investigate infarct growth over 72 hours assessed with diffusion weighted imaging on MRI after treatment with intravenous tocilizumab or placebo in patients above 18 years of age with acute ischemic stroke undergoing endovascular thrombectomy.

2025-521269-28-00Acute ischemic stroke

DrugTocilizumab

Oslo University Hospital HF

Nervous System Diseases

Norway, Denmark

12/03/2026

Phase II

INTRATUMORAL DNX-2401 ADMINISTRATION FOR RECURRENT AND REFRACTORY HIGH GRADE BRAIN TUMORS IN PEDIATRIC AND YOUNG ADULT PATIENTS

2024-515009-24-00High grade malignant brain neoplasm

Clinica Universidad De Navarra

Nervous System Diseases

Netherlands, Spain

11/03/2026

Phase II

Ultimate dePletion of autoReactive b cells using Obinutuzumab from sjÖgren's syndrome affected Tissues study- UPROOT study

2024-519884-16-00Sjögren's syndrome

DrugObinutuzumab

Radboud universitair medisch centrum Stichting

Immune System Diseases

Netherlands

11/03/2026

Phase II

B7981119 A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 16-Week Study Evaluating the Safety and Efficacy of Ritlecitinib (PF-06651600) in Adults with Moderate to Severe Hidradenitis Suppurativa

2025-522705-37-00HIDRADENITIS SUPPURATIVA

Pfizer Inc.

Skin and Connective Tissue Diseases

Germany, Poland, Spain, Greece

11/03/2026

Phase II

A Phase II, multinational, multicentre, double-blind, randomised, active-controlled, 3-way cross-over study to evaluate the therapeutic equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a versus CHF5993 pMDI 100/6/12.5 µg HFA-134a in subjects with mild to moderate asthma. [TRECONY]

2025-521456-35-00Mild to moderate asthma

Chiesi Farmaceutici S.p.A.

Respiratory Tract Diseases

Slovakia, Czechia, Romania, Latvia, Germany, Hungary, Bulgaria, Poland

11/03/2026

Phase II

A phase II, randomized, observer-blinded, controlled, parallel group clinical trial with decentralized elements to evaluate the safety and efficacy of PB-TX-01 in patients with chronic wounds colonized by Pseudomonas aeruginosa.

2024-517491-38-00Chronic wound colonized by Pseudomonas aeruginosa

PathoBlock Therapeutics GmbH & Co. KG

Bacterial Infections and Mycoses

Germany

10/03/2026

Phase II

A Phase 2a Multicenter Platform Study of Investigational Products for the Treatment of Adult Subjects with Idiopathic Pulmonary Fibrosis

2024-518013-25-00Idiopathic Pulmonary Fibrosis

AbbVie Deutschland GmbH & Co. KG

Respiratory Tract Diseases

Greece, Italy, Sweden, Germany, Portugal, Spain, France, Hungary, Poland, Bulgaria, Romania

10/03/2026

Phase II

Upadacitinib in adult patients with erosive mucosal Lichen Planus and Lichen Planopilaris: a prospective multicenter randomized placebo-controlled study. (Upa30-LP)

2025-522870-35-00Lichen

Centre Hospitalier Universitaire De Nice

Skin and Connective Tissue Diseases

France

09/03/2026

Phase II

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF GALVOKIMIG IN ADULT STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS

2025-522578-35-00Atopic Dermatitis

UCB Biopharma

Skin and Connective Tissue Diseases

Bulgaria, Czechia, Germany, Poland, Hungary

09/03/2026

Phase II

SGL-TX-PTDM: SGLT2i effect on PTDM development and kidney allograft function in kidney transplant recipients: A randomized, double-blind, placebo controlled, national multicenter trial

2024-518774-14-00Kidney transplant recipients

DrugDapagliflozin

Odense University Hospital

Not possible to specify

Denmark

09/03/2026

Phase II

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Assess Efficacy and Safety of Zasocitinib in Moderate to Severe Hidradenitis Suppurativa

2025-522831-33-00Hidradenitis Suppurativa

Takeda Development Center Americas Inc.

Skin and Connective Tissue Diseases

France, Poland, Netherlands, Germany

06/03/2026

Phase II

A Phase II, Randomized, Multicenter, Open-Label Study Evaluating the Efficacy and Safety of the Combination of Inavolisib Plus Enzalutamide Versus Physician's Choice of ARPI or Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer

2025-521327-67-00Metastatic Castration-Resistant Prostate Cancer

F. Hoffmann-La Roche AG

Neoplasms

Germany, France, Italy, Spain

06/03/2026

Phase II

A multinational, multicenter extension study to investigate the long-term safety, tolerability and efficacy of balinatunfib in adults with Crohn’s disease or ulcerative colitis

2025-522511-42-00Colitis Ulcerative, Crohn's disease

Sanofi-Aventis Recherche & Developpement

Digestive System Diseases

Belgium, Germany, Czechia, Netherlands, Spain, Austria, Italy, Greece, Croatia, Bulgaria, Poland, France, Romania, Hungary

06/03/2026

Phase II

KET01-IIT03: A Pilot, Open-label Phase II Trial of Adjunctive Treatment with Ketamine Hydrochloride Prolonged-Release Tablets (KET01) during the Initiation of Antidepressant Therapy in Major Depressive Disorder

2025-524841-28-00Major Depressive Disorder

Region Skane

Mental Disorders

Sweden

05/03/2026

Phase II

Up-titration of sulfonylurea (SU) in individuals with HNF1A- and HNF4A-MODY – A Steno MODERN-MODY project (MM-SUUP)

2025-524679-22-00Maturity-onset diabetes of the young type 3 (HNF1A-MODY), M…

Steno Diabetes Center Copenhagen

Hormonal diseases

Denmark

04/03/2026

Phase II

A Phase 2, Multi-center, Randomized, Dose-Ranging, Placebo-Controlled, Double-blind Study of the Relaxin Agonist R2R01 in Patients at High Risk for Cardiac Surgery Associated - Acute Kidney Injury.

2025-523037-25-00Patients at high risk for Cardiac Surgery Associated – Acut…

River 2 Renal Corp.

Pathological Conditions, Signs and Symptoms

Italy, Germany

04/03/2026

Phase II

Pilot study of the efficacy of nicotinamide (vitamin B3) in Leber's hereditary optic neuropathy - NICOLHON

2025-524343-13-00Leber's Hereditary Optic Neuropathy

Centre Hospitalier Universitaire D'Angers

Eye Diseases

France

03/03/2026

Phase II

A Phase 2 Study to Assess ADX-038 in Participants With Complement-Mediated Kidney Disease

2025-521752-26-00Complement-Mediated Kidney Disease

Adarx Pharmaceuticals Inc.

Male Urogenital Diseases

Spain, Italy

02/03/2026

Phase II

A phase II study of ficerafusp alfa (BCA 101) in combination with nivolumab in platinum refractory head and neck squamous cell carcinoma patients who progressed within 6 months after multimodal treatment for locally advanced disease ( BICARA)

2025-521437-88-00head and neck squamous cell carcinoma

Groupe Oncologie Radiotherapie Tete Cou

Neoplasms

France

02/03/2026

Phase II

Randomised EValuation of Therapies for microvAscuLar Injury in STEACS – REVITALISE Study

2025-522060-32-00STEMI (ST elevated Myocardial Infarction)

DrugAdenosine

CorFlow Therapeutics AG, CorFlow Therapeutics AG

Cardiovascular Diseases

Netherlands, Spain, France

02/03/2026

Phase II

Fibroblast markers to tackle fibrosis in immune-mediated inflammatory diseases

2025-522834-30-01Systemic sclerosis (SSc), Idiopathic pulmonary fibrosis (IP…

Amsterdam UMC Stichting

Skin and Connective Tissue Diseases

Netherlands

02/03/2026

Phase II

COMPARISON OF ZINC ACETATE DOSE REGIMENS (GALZIN VS. ET-700) FOR THE TREATMENT OF WILSON DISEASE: A PHARMACODYNAMIC 64CUCL2 PET/CT STUDY IN HEALTHY PARTICIPANTS

2025-523372-24-00Wilson's Disease

Region Midtjylland

Nutritional and Metabolic Diseases

Denmark

02/03/2026

Phase II

An open label extension study to evaluate the long-term safety and efficacy of subcutaneous lunsekimig in adult participants with asthma who participated in study DRI16762 or ACT18301. AIRPHRODITE

2025-522896-27-00Asthma

Sanofi-Aventis Recherche & Developpement

Respiratory Tract Diseases

Poland, Italy, Belgium, Sweden, Hungary, France, Germany, Spain, Denmark

02/03/2026

Phase II

A randomized, double-blind, placebo-controlled, Phase 2, dose-finding study to investigate the efficacy and safety of SAR445399 in participants with moderate to severe hidradenitis suppurativa

2025-522695-83-00Hidradenitis suppurativa

Sanofi-Aventis Recherche & Developpement

Immune System Diseases

Hungary, Spain, France, Belgium, Sweden, Germany, Italy

02/03/2026

Phase II

Efficacy and safety of Ursodeoxycholic Acid as a new therapy for the treatment of hepatorenal polycystic diseases, genetic study and determination of prognostic biomarkers.

2024-513644-28-00Hepatorenal polycystic diseases

Asociacion Instituto Biogipuzkoa

Digestive System Diseases

Spain

02/03/2026

Phase II

C5041018 - A Phase 2 Open-Label, Single Arm Study to Evaluate the Efficacy, Pharmacokinetics, and Safety of Etrasimod in Pediatric Participants with Moderately to Severely Active Ulcerative Colitis

2025-523100-77-00Ulcerative Colitis

Pfizer Inc.

Digestive System Diseases

Finland, Poland, France, Germany, Italy, Slovakia

27/02/2026

Phase II

A phase 2, single arm, open label, study on the safety and feasibility of Liver Isolated Oxaliplatin (LIOX) delivered via arterial access device for treatment of liver metastasis in colorectal cancer patients

2025-523261-25-00colorectal cancer

DrugOxaliplatin

UZ Leuven

Therapeutics

Belgium

27/02/2026

Phase II

POSITRON - PsilOcybin with pSychologIcal supporT foR cOcaiNe: a randomised controlled pilot feasibility trial of psilocybin with psychological support for cocaine use disorder

2024-515147-32-02Cocaine addiction

Trinity College Dublin

Mental Disorders

Ireland

27/02/2026

Phase II

A Phase 2a, Open-Label Pilot Study to Evaluate the Safety/Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of VTX2735 in Participants with Recurrent Pericarditis

2025-524784-20-00Recurrent Pericarditis

Zomagen Biosciences Limited

Cardiovascular Diseases

Belgium, France, Greece, Spain, Italy

27/02/2026

Phase II

PirtobrUtinib as frontline Therapy for elderly unfit/frail patient with MAntle cell lymphoma: a phase II study of the Fondazione Italiana Linfomi (FIL)

2025-521666-10-01Mantle Cell Lymphoma

Fondazione Italiana Linfomi Ets

Hemic and Lymphatic Diseases

Italy

26/02/2026

Phase II

STARS - Prospective, bayesian, randomized, controlled, open-label, parallel-group, phase II interventional study evaluating efficacy and safety of secukinumab versus standard of care in active severe Takayasu patients

2024-516215-24-00TAkayasu ARteritiS

Assistance Publique Hopitaux De Paris

Immune System Diseases

France

26/02/2026

Phase II

A double-blind, randomized, placebo-controlled, two arm, phase II clinical trial in parallel groups to evaluate the efficacy and tolerability of a rectal treatment with budesonide suppositories compared to placebo suppositories for amelioration of acute radiation proctitis symptoms in male patients aged 18 years or older with prostate carcinoma

2024-519359-27-00Acute radiation proctitis symptoms in male patients aged 18…

Dr. Falk Pharma GmbH

Digestive System Diseases

Germany, Austria

26/02/2026

Phase II

A Phase 2, Multicenter, Randomized, Double-blind Study of Safety and Efficacy of EL219 (Turletricin) versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy of Invasive Mould Infections (TREAT-1)

2025-522835-32-00Suspected Invasive Mould Infection

Elion Therapeutics Inc.

Bacterial Infections and Mycoses

Belgium, France, Spain, Italy

26/02/2026

Phase II

In vivo biological standardization of Olea europaea allergen extracts.

2025-523866-26-00Allergies

Asac Pharmaceutical Inmunology S.A.

Diagnosis

Spain

25/02/2026

Phase II

Effect of H2 inhalation therapy on early recurrence after atrial fibrillation ablation. Multicenter, open-label, randomized phase II controlled trial.

2024-520131-33-00atrial fibrillation

Centre Hospitalier Universitaire Grenoble Alpes

Cardiovascular Diseases

France

25/02/2026

Phase II

B7981118 - A Phase 2b Randomized, Double Blind, 12-Week Placebo Controlled Study With a 12-Week Double-Blind Extension Period to Evaluate the Efficacy, Safety and Tolerability of Ritlecitinib (PF 06651600) in Adult Participants with Chronic Spontaneous Urticaria

2025-522642-44-00CHRONIC SPONTANEOUS URTICARIA

Pfizer Inc.

Immune System Diseases

Spain, Germany, Bulgaria, Poland

25/02/2026

Phase II

Open-label, Uncontrolled, Multicenter Trial to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Children From 2 Years to Less Than 18 Years of Age with Immunoglobulin G4 related Disease (IgG4-RD)

2025-520988-41-00Immunoglobulin G4 related Disease (IgG4-RD)

DrugInebilizumab

Amgen Inc.

Immune System Diseases

Greece, Poland, Italy, Spain

25/02/2026

Phase II

A Phase 2 Double-blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of DT-101 in Adults with Major Depressive Disorder

2025-522784-15-00Major Depressive Disorder

Draig Therapeutics Limited

Mental Disorders

Czechia, Bulgaria, Poland

24/02/2026

Phase II

KEYMAKER-U01 Substudy 01J: A Randomized Phase 2 Umbrella Study With Rolling Arms of Investigational Agents for First-line Treatment of Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With KRAS G12C Mutations

2025-521939-36-00Participants with KRAS G12C-Mutant, Advanced or Metastatic …

Merck Sharp & Dohme LLC

Neoplasms

Italy, Poland, Spain, Finland, Netherlands, Greece

24/02/2026

Phase II

J2R-MC-YAAD: A Phase 2, Double-blind, Placebo-Controlled Study to Evaluate LY3537021 for the Treatment of Chemotherapy-Induced Nausea and Vomiting in Adult Participants With Malignant Disease

2025-522204-24-00Neoplasms, Drug-Related Side Effects and Adverse Reactions,…

Eli Lilly & Co.

Neoplasms

Romania, Spain, France, Italy

23/02/2026

Phase II

Open-label safety and efficacy trial of chlorhexidine and/or metronidazole pre-treatment followed by FB301 in women with bacterial vaginosis (BV)

2025-524362-20-00Bacterial vaginosis

Freya Biosciences ApS

Bacterial Infections and Mycoses

Germany

23/02/2026

Phase II

Obinutuzumab Treatment in Frequently Relapsing and Rituximab-Dependent Idiopathic Nephrotic Syndrome in Adults: a fully academic, single-arm, open, prospective, intervention trial

2025-523306-33-00Idiopathic Nephrotic Syndrome

Istituto Di Ricerche Farmacologiche Mario Negri

Immune System Diseases

Italy

23/02/2026

Phase II

Phase 2 study of iadademstat for the treatment of patients with essential thrombocythemia resistant/intolerant to hydroxyurea

2025-523864-19-00Essential Thrombocythemia

Oryzon Genomics S.A.

Hemic and Lymphatic Diseases

Spain

20/02/2026

Phase II

A phase II, multicentre, open label clinical trial evaluating the efficacy and safety of oral decitabine plus ivosidenib in adult patients with newly diagnosed acute myeloid leukemia older than 60 years old and/or who are ineligible for standard induction chemotherapy

2025-523238-17-00Acute myeloid leukemia

Fundacion PETHEMA

Neoplasms

Spain, Portugal

19/02/2026

Phase II

Efficacy and safety of a combined therapy with Alpha-Lipoic Acid and Benfotiamine in the symptomatic treatment of diabetic sensorimotor polyneuropathy - a prospective, randomized, controlled, parallel group, double-blind, double-dummy 3-arm trial

2025-521985-82-00Diabetic sensorimotor polyneuropathy (DSPN)

Woerwag Pharma GmbH & Co. KG

Nutritional and Metabolic Diseases

Hungary

18/02/2026

Phase II

Master Protocol Full Title: A Master Protocol for an Exploratory, Phase 2a, Proof-of-Concept Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis. ISA 1 Full Title: An ISA to Master Protocol ARGX-999-2-MG-2000 for an Exploratory, Phase 2a, Proof-of-Concept Study to Evaluate the Safety, Tolerability, and Efficacy of Empasiprubart IV as Add-On Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod.

2025-522492-28-00AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthe…

Argenx

Immune System Diseases

Spain, Poland, Germany, Netherlands, Greece, Italy, Belgium

18/02/2026

Phase II

Prevention of Ribociclib-related hepatotoxicity in breast cancer patients: a phase II, multicentre, open label, single arm trial of Silimarin.

2025-521651-22-00hormone receptor positive, HER2-negative breast cancer

DrugRibociclib

Fondazione Oncotech Impresa Sociale

Not possible to specify

Italy

17/02/2026

Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS), filtered. Derived from the EMA Clinical Trials Information System. Retrieved 7 November 2026. https://priyalifescience.com/clinical-trials-europe

Query this register directly

GET /api/export.php?register=trials-eu&format=json Try it now →

About this register

This register is built from the EU Clinical Trials Information System (CTIS), run by the European Medicines Agency: the single register for every trial authorised under the EU Clinical Trials Regulation (536/2014). CTIS held 12,788 trial records at the last sync on 07 Nov 2026, 03:17 UTC; this register shows the 2,557 most recently authorised of them, a stated recency window rather than the full archive. The list can be downloaded as CSV or JSON.

This page shows the 722 of those trials that match the filters currently applied.

How many clinical trials does CTIS hold?

CTIS held 12,788 trial records at the last sync. Of the 2,557 most recently authorised trials shown in this register, 789 are Phase III, and 722 match the filters currently applied. Trials are counted by authorisation, not by recruitment status, which CTIS does not publish in the same form as ClinicalTrials.gov.

Summary by phase

Trials by phase, 722 trials
Phase	Trials	Share
Phase II	722	100%

Most active sponsors

Lead sponsors with the most trials
Lead sponsor	Trials
Assistance Publique Hopitaux De Paris	17
AstraZeneca AB	16
Novartis Pharma AG	16
F. Hoffmann-La Roche AG	12
Merck Sharp & Dohme LLC	11
Amsterdam UMC Stichting	9
Eli Lilly & Co.	9
Pfizer Inc.	9
Unicancer	7
Universitair Medisch Centrum Groningen	7

Member states with the most trials

Member states by number of trials with a site there
Member state	Trials
Spain	279
France	274
Italy	246
Germany	235
Poland	175
Netherlands	134
Belgium	92
Denmark	75
Czechia	73
Bulgaria	68

→

Browse trials by member state

Spain (1074) France (933) Germany (893) Italy (777) Poland (614) Netherlands (544) Belgium (453) Czechia (340) Denmark (316) Hungary (255) Greece (237) Bulgaria (217) Romania (217) Austria (216) Sweden (200)

→

Browse trials by condition

Advanced solid tumors (23) Atopic Dermatitis (19) Non-Small Cell Lung Cancer (15) Obesity (14) Parkinson’s disease (14) Multiple sclerosis (13) Rheumatoid arthritis (13) Ulcerative Colitis (12) Breast Cancer (11) Prostate Cancer (10)

Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.